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Dear Readers
I hope all our readers are in good health and 
managing these uncertain times as best they can. 
The rapid spread of the Coronavirus Disease 2019 
(COVID-19) poses unprecedented challenges in 
Pakistan and across the globe. To serve the health care 
community at such a critical time, the LABRAD team 
has created a special issue pertaining to this global 
pandemic. One of the biggest lengthiest issue of its 
time, LABRAD offers a great variety of articles all 
related to COVID-19 to keep you informed on how 
to address this ever-evolving pandemic using the 
best available information. This issue also includes 
an interview of the Chair of the Department of 
Pathology and Laboratory Medicine and how she led 
the department in these challenging times. As the 
current pandemic problem extends to all parts of the 
country, we anticipate that this issue will be helpful to 
all our readers from across the country in providing 
high-quality, safe, effective and optimal care to their 
patients.
The day we decided to have a special issue of 
LABRAD on COVID-19 my whole newsletter 
team sprang into action. Whether, it was sending 
call for articles, gathering pictures (don’t forget to 
check the Polaroid section of LABRAD), taking 
appreciative inquiries (Best of the Past) reactions, or 
writing. Every single person in my team was ready to 
contribute and give it their best. The newsletter team 
remain connected throughout these past few weeks 
via WhatsApp and emails and compiled this issue 
completely remotely. The information in the current 
newsletter was conceived and compiled by staff, 
residents and faculty of the Departments of Pathology 
and Laboratory Medicine and Radiology.
Headed into the summer, there are umpteen questions 
we don’t have answers to. In this anxiety producing 
environment of pandemic, I would encourage all 
of you to stay positive. Keep on looking over the 
horizon and come up with innovative ideas to fight 
this COVID-19 pandemic. Stay connected to each 
other and keep discussing your ideas. The wealth of 
knowledge that can be gained from the experience of 
others should never be underestimated. Transmission 
of ideas should be sticky and as aggressive as 
COVID-19!
We truly are in this together, and that is precisely how 
we will get through it to a better future. Please take 
care, and stay safe.
Dr Lena Jafri 
Clinical Chemistry
From the Editor’s Desk
Coronaviruses are large enveloped RNA viruses. 
The human coronaviruses cause lower respiratory 
infections apart from being the causative agents 
of common cold and gastroenteritis in infants. 
COVID-19 or SARS-Cov-2, a type of beta-COV, is 
a novel strain of the Human Coronaviruses that was 
first identified in the latter part of 2019 as a cluster 
of pneumonia cases. In January 2020, the Chinese 
authorities identified a novel type of coronavirus, 
which was later named severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2). Until 
recently, only two beta coronaviruses — severe acute 
respiratory syndrome coronavirus (SARS-CoV) 
and Middle East respiratory syndrome coronavirus 
Pathophysiology of Lung Injury in Context 
with Novel Coronavirus 2019
Dr Qurratulain Chundriger and Dr Nasir Ud Din
Section of Histopathology
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(MERS-CoV) — have caused significant human 
morbidity and mortality. 
Pathophysiology: The COVID-19 has four major 
structural proteins: the spike surface glycoprotein, 
small envelope protein, matrix protein, and 
nucleocapsid protein. Coronaviruses exhibit a tropism 
for the epithelial membranes of the respiratory 
tract in particular. When a person is infected by 
COVID-19, the petal shaped glycoprotein spikes on 
the surface of the viral capsid attach to the epithelial 
cell via receptor binding domains of the Angiotensin 
Converting Enzyme II (ACEII) which is most 
abundant in type II pneumocytes. It is also found 
in other organs like gastrointestinal tract, kidney, 
lymph nodes, thymus, bone marrow, spleen and brain. 
The RNA of the virus is then endocytosed into the 
cytoplasm of the infected cell, where it first creates 
the viral RNA polymerase and then starts replicating. 
Multiple newly formed virions are then shed from the 
cell and infect other nearby cells. 
Clinical presentation: In 80 percent of cases, 
immune system fights back resulting in mild to 
moderate symptoms of cough, chest pain, fever and 
some degrees of shortness of breath. Upto 14 percent 
of COVID-19 infected individuals develop severe 
disease, most of these patients have a pre-existing 
condition that makes them highly vulnerable. These 
may be geriatric patients, immunocompromised 
individuals, chronic smokers, those with underlying 
pulmonary or cardiac dysfunction and diabetics to 
list a few. These patients present with hypoxemia or 
multi organ dysfunction and may require mechanical 
ventilation. 
ARDS and Radiological findings: About five percent 
cases develop Acute Respiratory Distress Syndrome 
or ARDS, which shows characteristic radiological 
findings on standard X-Rays and CT scans. According 
to the studies published so far, the imaging features 
of COVID-19 pneumonia are diverse, ranging from 
normal appearance to diffuse changes in the lungs. In 
addition, different radiological patterns are observed 
at different times throughout the disease course. One 
study showed slight predilection for the right lower 
lobe. The most common findings were ground glass 
opacities, variable degrees of septal thickening, 
nodules, cystic changes, pleural effusions and 
thickenings. Of these, patients with severe disease and 
those who succumbed, exhibited severe ground glass 
opacities and white lung on CT scans. 
Microscopic findings: Only a handful of studies 
have been published so far which have described the 
histopathological findings of patients with severe 
disease and those who died of COVID-19. The 
clinical picture is that of pneumonia and ARDS. The 
pathological findings are of Diffuse Alveolar Damage 
(DAD) which is the most common histopathologic 
correlate of ARDS. DAD shows an early exudative 
phase and a late organizing phase. In the exudative 
phase, there are rounded organizing plugs of exudate 
in the terminal bronchioles and protein-rich edema 
in the alveolar space, with fibrin-rich eosinophilic 
hyaline membranes along the surface of the alveolar 
septa (Figure 1).This results in inability of the lungs 
to perform the vital function of gaseous exchange 
through the damaged and so-called blocked 
pulmonary alveolar spaces. There can be proliferation 
of type II pneumocytes, accompanied by reactive 
nuclear changes in these cells, i.e. enlargement of the 
nuclei and mild atypia. The interstitium shows edema 
with scant number of inflammatory cells including 
lymphocytes, plasma cells and/or neutrophils, 
depending on the underlying etiology. The term 
“diffuse” refers to complete involvement of the 
pulmonary lobule and not necessarily the entire lung 
tissue. One study has also described multinucleated 
syncytial cells with atypical enlarged pneumocytes 
characterized by large nuclei, amphophilic granular 
cytoplasm, and prominent nucleoli were identified in 
the intra-alveolar spaces, showing viral cytopathic-
like changes. Viral inclusions were not identified. 
Large areas of intra-alveolar hemorrhages and intra-
alveolar fibrin cluster formation were observed in 
another study. All these changes have been described 
in autopsy findings of COVID-19 decedents, who 
had increased weights of lungs due to edema or 
consolidation and adhesions grossly. The organizing 
phase may show interstitial thickening and fibrinoid 
necrosis of small vessels along with alveolar edema 
and pleural fibrosis with adhesions. Some or may 
be most of the cases under the microscope show a 
variable mixture of areas of both exudative as well as 
organizing phases. Findings representing the fibrotic 
phase (e.g. dense collagenous fibrosis, architectural 
remodeling) are not reported so far. 
Figure 1. Lung tissue showing formation of hyaline 
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membranes which line the alveolar spaces with loss of 
alveolar pneumocytes. In addition, there are changes 
of pneumonia i.e. interstitial inflammation and 
widening, along with congested vessels and areas of 
hemorrhage. 
No significant histopathological abnormalities were 
reported in other tissues like the heart and liver in 
patients who died of COVID-19. These organs showed 
changes pertaining to either an underlying condition, 
like liver cirrhosis and or changes related to prolonged 
hospitalization and drug related injury, such as 
microvesicular steatosis in hepatocyte lobules. Only 
few autopsy studies and a couple of studies of core 
biopsies from patients who recovered from COVID 
related illness have been reported in the literature so 
far, all of these from china and the western world. 
In Pakistan, we are way behind them as autopsies 
are not routinely performed for non-medico legal 
purposes and there is no trend of doing core biopsies 
from patients with any degree of symptomatic 
COVID-19 illness. As reports of atypical presentation 
are continuously being made, this strain of the 
coronavirus presents an entire horizon of clinical, 
radiological and pathological features to be explored.
The entire world is experiencing an outbreak caused 
by the novel Corona virus that originated from 
Wuhan, China in December 2019. The disease was 
officially announced as a pandemic by World Health 
Organization (WHO) on the 11th of March 2020.  At 
first, the disease appeared in a few clusters affecting 
individuals with advanced age or co-morbidities; 
however, it is now widespread. COVID-19 can cause 
severe pneumonia and fatal respiratory disease 
especially acute respiratory distress syndrome 
(ARDS). The predominant clinical features of 
COVID-19 infection are fever, fatigue, malaise, 
dry cough and other respiratory symptoms. Early 
detection and diagnosis of this highly contagious 
disease is vital to control the outbreak; hence, it is 
important to separate suspected cases and contacts. 
In the present times the diagnosis is mainly based on 
the patient’s epidemiological history, clinical features, 
laboratory tests especially the reverse transcriptase 
polymerase chain reaction (RT-PCR) for COVID-19 
and chest imaging features.  The radiologist plays an 
important role in the early diagnosis and identification 
of a suspected COVID-19 individual which can be of 
great help not only to the patient but also for public 
health surveillance and response authorities.  This 
short communication briefly introduces the chest 
X-ray and CT imaging features of this novel corona 
virus infection with focus on the value of imaging in 
its diagnostic workup.    
Chest X Ray
Chest x-ray is not routinely performed in the clinical 
workup of a suspected COVID-19 patient because 
it is not sensitive in the early stage of the disease. 
However, with the progression of disease beyond the 
early stage, the chest x-ray may show multiple patchy 
opacities, predominantly at peripheral and bases, and 
in bilateral lung fields. (Figure 1 & 4a) With further 
severity of disease, there develops confluence of 
Imaging in COVID-19 Pandemic: Salient 
Features 
Dr Shaista Afzal
Radiology
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opacities that results in “whited out lung”. Pleural 
effusion has also been reported in severe cases. The 
findings have been reported to develop over the time 
course of the disease.
CT (Computed Tomography) Chest 
For COVID-19 diagnosis, RT-PCR is regarded as the 
reference standard. However, as reported in recent 
studies, CT chest has shown a sensitivity of 98%, 
especially in patients with false negative RT-PCR.
CT chest also plays an important role in the evaluation 
of therapeutic efficacy and monitoring of disease 
progression. The common imaging features of 
COVID-19 on CT chest are ground glass opacities 
which are multiple, patchy, bilaterally distributed 
mostly along the bronchovascular bundle, with or 
without consolidation, and predominantly in the 
posterior and peripheral lungs. (Figure 2 , 3 &4b) 
Other features include reversed halo sign, crazy 
paving pattern and airway changes. Pleural changes 
comprising of pleural thickening and pleural effusion 
have also been reported, with the former feature being 
more prevalent. Poor prognosis is reported in patients 
who develop pleural effusion. Recent literature 
further reports the presence of lymphadenopathy and 
pericardial effusion in critical COVID-19 patients.
Figure 1: X ray chest, AP sitting projection, shows multiple 
inhomogeneous opacities in the periphery of bilateral lung fields  
Figure 2: Unenhanced CT chest examination: Bilateral, basal, ground 
glass opacities with some crazy paving. The disease is predominantly 
peripheral in distribution with perihilar sparing.                                                                             
Classic imaging features of COVID-19 infection are seen                                                               
Figure 3: Multiplanar reformatted coronal image, with HRCT protocol. 
There is evidence of groundglass appearance and patchy areas of 
consolidation in the periphery of bilateral lung fields, predominantly on 
the right side in keeping with COVID-19.
Figure 4a: X-ray chest AP sitting view.
Patchy areas of consolidation in bilateral lung fields
predominantly involving subpleural location
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The global outbreak of novel coronavirus, SARS-
CoV-2 (COVID-19), caused over 100,000 deaths 
and more than 1 500,000 infected sending several 
countries to lock down. COVID-19 is caused by 
SARS-CoV-2 which belongs to a family of beta 
corona viruses. It was first discovered in the Wuhan, a 
city in the Hubei Province of China in 2019. It belongs 
to the same subgenus as that of the severe acute 
respiratory syndrome (SARS) virus but to a different 
clade. SARS-CoV-2 virus appears spherical in shape. 
It has spike like proteins protruding from the surface 
of the virus particle. Recent work shows that SARS-
CoV2 attaches to human cell receptor angiotensin-
converting enzyme two (ACE2) using its spike like 
proteins which than undergoes a structural change 
allowing the viral membrane to fuse with the human 
cell membrane. The viral genes then enter 
into the host producing more viruses.
Transmission is through droplets and the incubation 
period is 14 days following exposure. Patients who 
are affected with SARS-CoV2 presents with fever 
and acute respiratory symptoms including cough 
and dyspnea. In case of severe manifestation, 
patient presents with pneumonia having bilateral 
infiltrates on chest X-ray.  Patients with compromised 
immune responses including old age or underlying 
comorbidities are reported to develop more severe 
disease. The global fatality rate is reported to 
be around two percent. People who are at risk 
of getting COVID 19 are the ones who live in 
or have travelled to the areas where community 
transmission has been reported or the ones who 
have had a close contact with confirmed cases. 
Patients suspected of COVID-19 should undergo 
testing for SARS-CoV2 along with testing for other 
possible respiratory pathogens. Appropriate sample 
including upper respiratory specimen (oropharyngeal 
and nasopharyngeal swab) or lower respiratory 
specimen (sputum) is sent to the lab in a viral/
universal transport medium. Nucleic acid extraction 
Qualitative Real-Time RT-PCR For Detection 
of SARS-Cov-2 RNA
Dr Kiran Iqbal and Dr Najia Ghanchi 
Molecular Pathology 
Figure 4b: HRCT examination of the above patient (4a), Multifocal, 
patchy areas of dense groundglass haze as well as scattered 
consolidations identified in both lung fields with predominant subpleural 
involvement, appearances are highly suggestive of COVID pneumonia.  
Conclusion
In the present situation, imaging of COVID-19 
patients especially with CT Chest is very valuable 
because it shows characteristic imaging features 
of COVID-19 infection. This shall enable 
frontline physicians to diagnose patients even 
when laboratory results are false negative. An 
early diagnosis with the help of imaging may 
thus facilitate containment of the disease and 
overcoming of the outbreak.  
Figure 1: Structure and genome organization of SARS-CoV-2. 
A) structure of SARS-CoV 2 viron. 
B) Relative positions of amplicon targets on SARS-CoV genome.
N: nucleocapsid, ORF: open reading frame.
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Patients tested positive should be isolated and 
provided with supportive treatment. Antiviral 
treatment for COVID-19 is under investigation. 
Patients with mild infections can be managed at home 
provided they stay at home in a separate room from 
other people and animals in the house. They should 
wear a facemask when with someone or when visiting 
health care settings. No vaccine or specific treatment 
for COVID-19 is available and care is supportive
Many aspects of the virus and disease are still not 
understood. A better understanding will be needed to 
provide improved guidance.
is performed and the sample is subjected to real-
time reverse transcription polymerase chain reaction 
(rRT-PCR) for the detection of SARS-CoV2 RNA. 
The viral genes targeted for testing include the N, E, 
S and RdRP genes. E gene is targeted as a first line 
screening assay for pan-Sarbecovirus detection. For 
confirmation RdRp and ORF1/a non-structural gene 
are being tested. PCR detects SARS-CoV-2 RNA that 
are detectable in nasopharyngeal and Oropharyngeal 
swab samples during infection. Positive results are 
indicative of SARS-CoV-2 RNA detection, but may 
not represent the presence of transmissible virus. 
Negative results do not preclude SARS-CoV-2 
infection and should not be used as the sole basis for 
patient management decisions and must be correlated 
with clinical, patient history, and epidemiological 
information.
The 2019 novel coronavirus (COVID-19) presents 
with a variety of phenotypes that range from 
asymptomatic to profound, rapid multiple organ 
dysfunction syndrome (MODS) and death. 
Proposed mechanisms for MODS in COVID-19 are 
multifactorial but include a hypercoagulable state 
with micro and macro-circulatory thrombosis.
Recent observations and autopsy findings suggest 
that respiratory failure in COVID-19 is not driven 
by the development of the acute respiratory distress 
syndrome (ARDS) alone, but that 
(microvascular) thrombotic processes 
may play a role as well. This may 
have important consequences for the 
diagnostic and therapeutic management 
of these patients. There is a strong 
association between D-dimer levels, 
disease progression and chest CT features 
suggesting venous thrombosis.
A strong predictor of mortality is 
disseminated intravascular coagulation 
(DIC). A significant increase in D-dimer 
and prothrombin with a decrease in fibrinogen in 
non-survivors at days 10-14 is also reported. This 
highlights the importance of regular and continued 
monitoring of these levels.
D-Dimer is a degradation product of cross-linked 
fibrin and reflects blood clot formation and its 
subsequent fibrinolysis. Testing uses an enzyme-
linked immunoabsorbent assay (ELISA) or microlatex 
agglutination assay . D-dimer has a very high 
sensitivity for thrombotic disease, but its specificity 
Coagulopathy and Anticoagulants in COVID-19 
Dr Kanta Devi
Hematology Transfusion Medicine
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is poor. Elevated D-dimer (above 1 μg/mL) was a 
strong and independent risk factor for death in this 
population.
Pathology Findings
Microvascular thrombosis is hypothesized to 
be involved in hypoxemic respiratory failure in 
some patients with COVID-19. Autopsy studies 
to date have been limited, with some suggesting 
microvascular thrombosis and others showing 
pulmonary hemorrhage. Whether the coagulation 
cascade is directly activated by the virus or whether 
this is the result of local or systemic inflammation 
is not completely understood. High plasma levels 
of proinflammatory cytokines (interleukin-2, 
interleukin-7, granulocyte colony-stimulating factor, 
IP10, MCP1, MIP1A and tumor necrosis factor-α) 
have been observed in COVID-19 patients admitted to 
intensive care units. . While many pro-inflammatory 
cytokines trigger the coagulation system, showed 
that the increase in IL-6 was discrepant with 
the elevations in D-dimer; IL-6 levels appeared 
to increase only 13 days after disease onset, 
whereas D-dimer levels were already 10-fold 
increased by that time. This observation suggests 
that the very high D-dimer levels observed in 
COVID-19 patients are not only secondary to 
systemic inflammation, but also reflect true 
thrombotic disease, possibly induced by cellular 
activation that is triggered by the virus.
l Bottom Line: this report supports the concept of 
hypercoagulative status, showing high frequency of 
pulmonary microthrombosis
Role of Antithrombotic Therapy
Notably, a Chinese single-center retrospective 
cohort study (Tonghi hospital) of 449 consecutive 
patients classified as having severe COVID-19 
indicates that prophylactic doses of heparins might 
be associated with improved survival (20 percent) in 
patients with evidence of sepsis induced coagulopathy 
(SIC)/DIC). Severe COVID-19 was defined as either 
a respiratory rate ≥30/min, arterial oxygen saturation 
≤93 percent at rest, or PaO2/FiO2 ≤300 mmHg. 
Exclusion criteria included bleeding diathesis, hospital 
stay <7 days and lack of information of coagulation 
parameters and medications.  Heparin was associated 
with lower 28-day mortality.
American Society of Hematology recommends all 
hospitalized patients with COVID-19 should receive 
thromboprophylaxis with LMWH or fondaparinux 
(suggested over unfractionated heparin to reduce 
contact) unless the patient is judged to be at increased 
risk of bleeding. In patients with a history of heparin-
induced thrombocytopenia (HIT) use fondaparinux.
Diffuse Alveolar Damage
A
C
B
D
Microthrombi in Small
Pulmonary Arterioles
Microthrombi in Small
Pulmonary Arterioles
Microthrombi in Small
Pulmonary Arterioles
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Procalcitonin (PCT) is the peptide precursor of 
calcitonin, a hormone that is synthesized by the 
parafollicular C cells of the thyroid and involved 
in calcium homeostasis. Procalcitonin arises from 
endopeptidase-cleaved preprocalcitonin. It is also 
produced by the neuroendocrine cells of the lung and 
intestine and is released as an acute-phase reactant in 
response to inflammatory stimuli, especially those of 
bacterial origin. It is a biomarker that exhibit greater 
specificity than other pro-inflammatory markers (eg, 
cytokines) in identifying sepsis and can be used in the 
diagnosis of bacterial infections.
PCT production is induced in response to microbial 
toxins and to certain bacterial-induced cytokines, 
particularly interleukin (IL)-1β, tumor-necrosis 
factor (TNF)-α and IL-6, and is released in the 
bloodstream where it can be measured  Conversely, 
PCT production is attenuated by certain cytokines 
released in response to a viral infection, particularly 
interferon-γ (IFN-γ). This selective cellular 
mechanism makes PCT a useful diagnostic biomarker, 
which is more specific for bacterial infections and 
helps to distinguish bacterial infections from other 
inflammatory reactions or viral infections. The raised 
Procalcitonin level during inflammation is associated 
with bacterial end toxin and inflammatory cytokines.  
Increased levels of serum procalcitonin in response 
to viral infections and noninfectious inflammatory 
stimuli such as autoimmune disease and chronic 
inflammatory processes are much less pronounced, 
rarely exceeding 0.5 ng/mL. The reference cutoffs are 
shown in Table 1.
PCT levels intensify within two–four hours of 
infection and the maximum level is reached by six–
eight hours and with continued infection or sepsis the 
elevated level persists and decreases once infection is 
controlled. Its half-life is about 20–24 hours. Its levels 
persist as long as the inflammatory process continues 
and the level correlate with the severity of sepsis. The 
applications or indications of testing PCT include to:
	 l Aid in the diagnosis and risk stratification of  
  bacterial sepsis.
	 l Aid in distinguishing bacterial from viral 
  infections, including meningitis.
	 l Screen therapeutic response to antibacterial 
  therapy and reduce antibiotic exposure.
l	Aid the preference and timing of the initiation 
of antibiotic treatment (Procalcitonin Algorithm) 
Serum Procalcitonin - A Marker to 
Differentiate Bacterial from Viral Infection
Dr Zaib-un-Nisa
Clinical Chemistry
Table 1: Interpretation of Procalcitonin Levels:
Test Name
Pro Calcitonin
Reference Cutoffs 
< 0.5 ng/mL represents a low 
risk of severe sepsis and/or 
septic shock
2.0 ng/mL represent a high risk of 
severe sepsis and/or septic shock.
Conditions associated
•  Localized mild-to-moderate bacterial infection
•  Noninfectious systemic inflammatory response
•  Untreated end-stage renal failure
•  Bacterial sepsis
•  Severe noninfectious inflammatory stimuli (e.g., major burns, 
 severe trauma, acute multiorgan failure, major abdominal or 
 cardiothoracic surgery).
•  Medullary thyroid carcinoma (may exceed 10,000 ng/mL).
 Figure 1: Algorithm for use of PCT for antibiotic Therapy. 
(Reference:Vijayan et al. Journal of Intensive Care (2017) 5:51; DOI 
10.1186/s40560-017-0246-8)
Serum PCT
level during
sepsis
10ng/ml
2ng/
ml
0.5ng/
ml
0.05ng/
ml
PCT algorithm
for antibiotic
therapy
>0.5ng/ml
0.25-
0.5ng/ml
0.1-
0.25ng/ml
<0.1ng/
ml
Antibiotic
strongly
encouraged
Antibiotic
encouraged
Antibiotic
discouraged
Antibiotic
strongly
discouraged
Septic
shock
Severe
sepsis
Local
infection
sepsis
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for improved antibiotic stewardship. The figure 1 
shows the algorithm of PCT which can be utilized in 
antibiotic therapy.
l Aid in the diagnosis of systemic secondary 
infection after surgery and in severe trauma, burns, 
and multiorgan failure.
COVID-19 and Procalcitonin
The PCT is now considered an important parameter 
for earlier identification of COVID-19 patients at 
risk of developing bacterial co-infection. A report by 
Guan W. et al. (NEJM Feb 2020) showing data from 
different medical centers of China, including 1099 
COVID-19 patients  reported that their PCT levels 
were low (<0.5 µg/L) in > 96 percent of cases with 
low disease severity and absence of adverse outcome 
(combined endpoint of ICU admission, invasive 
ventilation, death). Another report by Zhou et al. 
reported that COVID-19 patients may even present 
with PCT levels <0.25µg/L or even below 0.1 µg/L 
(Lancet Mar 2020). PCT testing on admission seems 
to be a valuable additional piece of information to 
aid in early risk assessment and rule-out of bacterial 
coinfection in COVID-19 patients.
COVID-19 is a viral disease, for which there is 
currently no treatment. It is therefore necessary 
to explore biomarkers to determine the extent 
of lung lesions and disease severity. New 
coronavirus pneumonia (COVID-19) is a health 
emergency due to its high infectiousness and high 
case fatality in critically ill patients. Clinical 
monitoring and appropriate treatment strategies 
were essential to improve case fatality. The 
pathological and physiological processes and 
diagnostic methods of COVID-19 are still in the 
exploratory stage.
The CRP levels are used in the early diagnosis 
of pneumonia and patients presenting with 
severe pneumonia have high CRP levels. 
Correlation between CRP levels, lung lesions, 
and disease severity to provide reference for 
clinical treatment. It was first discovered in a 
patient with lobar pneumonia in 1930 by Tillet 
& Francis. The CRP is a protein produced in 
response to infection or inf lammation and it 
is widely used in clinical tests to diagnose 
and manage patients with sepsis. It is an acute 
phase reactant whose synthesis in the liver is 
up- regulated by Interleukin-6. Its response is 
stronger in acutely ill patients and levels decrease 
as patients recover. It should be used cautiously 
in patients with sepsis, as it is also a marker of 
inf lammation that also increases after surgery, 
burns, myocardial infarctions, and rheumatic 
diseases. A rapid decrease in CRP levels has 
been reported to correlate with good response to 
initial antimicrobial therapy in septic patients. 
The plasma half-life of CRP is 19 hours. The 
sensitivity and specificity of CRP as a marker for 
bacterial infections are 68–92 percent and 40–67 
percent, respectively. 
Although CRP does not normally elevate 
significantly in mild viral respiratory infections, 
levels have shown to increase in severe cases, 
such as in avian inf luenza H1N1 and H7N9, 
and during SARS epidemics in 2003. A 
similar significant increase of CRP has also 
been reported in COVID-19 patients. One 
possible explanation for this phenomenon is the 
overproduction of inf lammatory cytokines that 
take part in the defense against the pathogen, but 
also cause more severe symptoms and damage 
in lung alveoli and stimulate CRP production. 
Therefore, CRP testing may be useful in the 
initial evaluation of coronavirus patients. It 
provides an important clinical evaluation index, 
and levels can ref lect disease changes, especially 
for patients who are not in critical condition.
Role of C-Reactive Protein (CRP) in COVID-19
Ms Iffat Arman
Clinical Chemistry
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Coronavirus disease 2019 (COVID-19), caused by 
severe acute respiratory syndrome coronavirus Two 
(SARS-CoV-2) has emerged as a life-threatening 
global pandemic. The role of clinical laboratories 
begins with the etiological diagnosis based on 
real-time reverse transcription polymerase chain 
reaction and extends beyond to disease surveillance, 
monitoring disease severity, evaluating prognosis 
and therapeutic drug monitoring via numerous 
biochemical markers. 
The table below summarizes the role of various 
biochemical markers alongside their interpretation 
and clinical significance in COVID-19 cases. 
A Snapshot of the Biochemical Markers Used 
in the Monitoring of COVID-19 Cases
Dr Sibtain Ahmed
Clinical Chemistry
Biochemical Test Specimen 
Type
Clinical Significance Abnormality 
in COVID-19 
Cases
Interpretation
Albumin Serum Useful for assessment of 
nutritional status and liver 
dysfunction
Decreased
Increased
Impairment of liver function, 
malnourished
Dehydration
Lactate Dehydrogenase Serum Useful for assessment of tissue 
damage
Increased Indicate severe shock, and 
hypoxia. Widespread tissue 
damage particularly pulmonary 
injury
Alanine 
Aminotransferase 
(ALT)
Serum Useful for assessment of liver 
dysfunction associated with 
hepatic necrosis
Increased Destruction of hepatocytes
Aspartate 
aminotransferase (AST)
Serum Useful for assessment of 
myocardial infarction, acute liver 
cell damage
Increased Tissue damage, particularly 
liver injury
Creatinine Serum Useful for diagnosing and 
monitoring treatment of acute 
and chronic renal diseases
-Estimation of Glomerular 
filtration rate
-Adjusting dosage of renally 
excreted medications
Increased Renal injury, declining renal 
function, therapeutic dose 
adjustment
Procalcitonin Serum Useful for diagnosing Diagnosis 
of bacteremia and septicemia
Increased bacterial coinfection in those 
developing severe form of 
disease
C-reactive protein Serum Useful for detecting systemic 
inflammatory processes
Increased Increase associated with 
severity of viremia and sepsis, 
associated with prognosis
Lactate Plasma Useful for monitoring of lactic 
acidosis
Increased Septic Shock, associated with 
prognosis
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Coronavirus disease 2019 (COVID‐19) is caused by 
a novel coronavirus recently renamed as severe acute 
respiratory syndrome coronavirus 2 (SARS‐CoV‐2). 
It is transmitted primarily via droplets, respiratory 
secretions and direct contact. The presence of the virus 
in feaces and blood suggest other probable modes of 
transmission. Since the start of this epidemic it had 
been speculated that it has the potential to reduce the 
supply of blood components and adversely affect blood 
system activities. Blood services across the world, 
therefore, took steps to assess, plan, and respond 
appropriately and proportionately. AKUH blood bank 
took the blow very early, when on 26th February 
2020, the first patient of Pakistan was diagnosed with 
SARS-CoV-2 infection in Karachi, resulted in the 
closure of all schools in Sindh by the government. On 
27th February, we had a well-planned annual blood 
donation camp at one of the leading schools in Karachi 
which got canceled at the eleventh hour because of the 
school closure. That camp was promising to collect the 
donation of at least 500 blood units. 
To maintain safe and adequate blood supply during 
this outbreak we took the following measures:
1. Reduce the potential risk of transmission 
through the transfusion of blood
Transmission of a respiratory virus by transfusion 
is theoretically possible, but unlikely based on 
precedent. Any actions taken to reduce risk are 
therefore precautionary.
On 19th March, in the pre-donation assessment, we 
added the following questions to be asked from the 
potential blood donors:
• Within the last 14 days, travel history of the donor 
 (traveled to Karachi from an outside country or 
 from inside country)
• Within the last 14 days, travel history of any 
 person who has been in close contact with the 
 donor (traveled to Karachi from an outside 
country or from inside country)
• The donor has a fever within last 14 days
• Cough, cold, flu or sore throat in the last 14 days
If the answer to any of these questions is YES, he is 
deferred from donating blood for 28 days. 
Since March 2020, we have deferred a total of 335 
blood donors out of which 35 donors were deferred 
due to the above-mentioned points.  
2. Alleviate the impact of reduced availability of 
blood donors
The reduction of donor numbers during the outbreak 
is a major risk for the blood bank. So, we considered 
the sufficiency risk early to enable preparedness 
and response. Blood donation numbers were closely 
monitored so that measures can be taken quickly to 
pre-empt any decline in donor attendance. Our aim 
has been to balance donor deferrals for protecting the 
blood supply with an estimate of any negative impact 
on the adequacy of the blood supply. Furthermore, 
we conveyed our concerns about the shortage of 
blood supply to clinical areas and ask them to ensure 
exchange donation by sending blood donors to the 
blood bank, while arranging blood products for their 
patients. At the time of writing, we have been able to 
equilibrate the supply with demand. But as the month 
of Ramadan has approached we fear a decrease in 
the number of blood donations and working upon the 
strategies to overcome it.
3. Mitigate the risk of staff and donor exposure to 
SARS-CoV-2 
Any transmission from a donor is far more likely 
to occur through the respiratory route than through 
parenteral routes (including phlebotomy during blood 
donation). It is possible that an infected donor who 
is asymptomatic, pre-symptomatic, or has very mild 
symptoms may infect other donors and staff. 
Besides following the standard laboratory biosafety 
practices advised by laboratory management we 
adopted the following workflow for blood donation:
AKUH Blood Bank During SARS-COV-2 
Outbreak
Muhammad Hasan
Section of Hematology & Transfusion Medicine 
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4. Collection of Convalescent Plasma 
While specific new drugs and vaccines are being 
researched for COVID 19, certain drugs that are 
already present in medical arsenal are under trial 
too. One investigational treatment being explored 
for COVID-19 is the use of convalescent plasma 
(CP) collected from recovered COVID-19 patients. 
Convalescent Plasma is a source of passive immune 
therapy- the administration of specific antibodies 
against a given agent for preventing or treating 
an infectious disease due to that agent. Section of 
Hematology & transfusion medicine in collaboration 
with Section of Infectious disease has started an 
open-label clinical trial, in which we are collecting 
plasma from the persons (CP donors) who have 
been recovered from SARS-CoV-2 infection and 
transfusing it to the patients having active severe 
COVID-19, to assess the efficacy and safety of this 
therapy.
Coronaviruses are a large family of single-stranded 
RNA viruses that can infect humans as well as 
animals. In humans, coronavirus infection is typically 
associated with mild to moderate respiratory illnesses 
such as the common cold Sometimes these viruses can 
mutate and jump to humans, which results in severe 
respiratory illness, as in the outbreak of Severe Acute 
Respiratory Syndrome (SARS-CoV) in 2002 and, more 
recently, Middle East Respiratory Syndrome (MERS-
CoV) in 2012. Coronavirus disease 2019 (COVID-19) 
was discovered in Hubei Province, China in December 
2019. Initially, the new virus was called 2019-nCoV. 
Subsequently, the task of experts of the International 
Committee on Taxonomy of Viruses (ICTV) termed it 
the SARS-CoV-2 virus as it is very similar to the one 
that caused the SARS outbreak (SARS-CoVs).
Coronavirus is an RNA virus consisting 
of positive-sense single-stranded RNA of 
approximately 27–32 kb. The genome encodes 
27 proteins including an RNA-dependent RNA 
polymerase (RdRP) and four structural proteins. 
The four structural proteins include the spike 
surface glycoprotein (S), small envelope protein 
(E), matrix protein (M), and nucleocapsid protein 
(N). 
Single-stranded RNA genome of SARS-CoV2
Routine confirmation of COVID-19 cases is based 
on detection of COVID-19 virus nucleic acid (RNA) 
by real time RT-PCR assays. A major advantage of 
real-time RT-PCR assays is that amplification and 
analysis are done simultaneously in a closed system 
to minimize false-positive results associated with 
amplification product contamination. 
Sequencing 
Sequencing played an important role in identifying 
Significance of COVID-19 Whole Genome 
Sequencing 
Samina Ghani
Molecular Pathology
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the novel coronavirus SARS-CoV-2. Following next-
generation sequencing, where partial and full genomes 
were obtained, Sanger sequencing was used in the 
connection of viral contigs, resulting in acquisition 
of the sequence of full length genomes. Additionally, 
by analyzing these genomes and comparing to other 
known coronaviruses, it was determined that the virus 
originated in an animal reservoir that evolved from 
bats, with a likely intermediate animal host. Whole 
genome sequencing will help understand whether 
multiple strains of Covid-19 exist among population 
and dispersal patterns of mutations in various 
geographic areas. Data generated through WGS may 
predict effectiveness of the response to drugs and 
variation from one strain to another.
Next-generation Sequencing (NGS) 
During viral pandemics, next-generation 
sequencing (NGS) is proven as a valuable tool for 
the characterization and detection of viruses in the 
environment, animals, and humans. The biggest 
challenge during any outbreak is to predict the pattern 
or evolution and disease spread, especially with RNA 
viruses such as the Covid-19, which have a very high 
genetic variability making it difficult to understand 
the transmission pattern, number of active strains and 
their geographical locations, or if a person is affected 
with multiple strains. By sequencing the entire viral 
genome, researchers can pinpoint the genetic changes 
that occur in the virus as it spreads through the 
population. This approach is useful to
1) Understand the transmission of the virus
Understanding changes in the genetic sequence of 
the viral genomes collected from different patients 
allows researchers to build a viral ‘family tree’ and 
contribute to efforts to monitor disease spread within 
and between populations over time. This can help 
with identification of infection ‘hot spots’, or of super 
spreaders – individuals who transmit the infection 
to a larger than expected number of people. This 
information is valuable for planning targeted public 
health interventions to reduce disease spread.
2) Design treatments and vaccines
Understanding the viral DNA sequence will assist 
researchers designing therapies and vaccines that 
target specific features of the virus. It will also allow 
better understanding of how therapy and vaccine 
effectiveness might change as the virus evolves.
3) Monitor viral evolution
Continually tracking the virus will alert researchers to 
genetic changes that might give rise to less virulent or 
more virulent strains. Early warning of a more virulent 
virus or emergence of treatment resistance will be vital 
to support measures to minimize disease spread and for 
designing new treatments and vaccines.
Convalescent plasma: Convalescent plasma refers to 
plasma from an individual who has recovered from an 
infection. It is a means of antibody transfer to provide 
passive immunity until the individual can develop an 
active immune response, with the hope that clinical 
outcomes can be improved in the recipient. Convalescent 
plasma is not routinely available, nor is it a licensed FDA 
product; instead, it has been made available for specific 
agents at times of disease epidemics or pandemics. 
During the 2019-2020 coronavirus disease (COVID-19) 
pandemic, community blood centers around the world 
are establishing programs for recovered individuals 
to donate convalescent plasma. Once the pandemic 
subsided, convalescent plasma is likely to become 
unavailable. Monoclonal antibodies with neutralizing 
potential are another approach, although this requires 
additional development and manufacturing steps. 
Convalescent plasma is generally most appropriate 
for individuals who are severely ill and do not have 
access to better alternatives. 
Convalescent Plasma Therapy for COVID-19
Dr Anila Rashid
Haematology & Transfusion Medicine
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Historical Use: Prior to SARS-CoV-2, convalescent 
plasma was used for treating the following severe 
acute respiratory syndromes 
Coronaviruses and Convalescent Plasma Therapy
SARS-CoV (2003 SARS epidemic) – There was 
reduced mortality (on the order of 7-23 percent lower 
mortality). There was a reduced hospital length 
of stay, especially when convalescent plasma was 
administered within two weeks of symptom onset. No 
major complications were reported.
Influenza viruses and Convalescent Plasma 
Therapy
H1N1-pdm09 (2009 pandemic) – One study reported 
an 80 percent reduction in mortality, especially 
with early treatment. There was a reduced length of 
intensive care stay. 
H5N1 (avian influenza; several outbreaks) – Non-
significant benefits (one study).
H1N1 (1918-1919 flu epidemic) – There was reduced 
mortality (approximately 20 percent reduction). 
Convalescent blood was used rather than plasma. 
Plasma Administration – Criteria for optimal 
preparation of plasma (or hyperimmune globulin) 
include 
l	High enough titer of neutralizing antibody to be  
 effective
l	Lack of infectious particles (either the target   
 pathogen or others)
l	Blood type compatible (ABO; Rh in women of  
 reproductive potential) 
l	Evidence for efficacy and lack of harm, ideally from  
 randomized trials or prospective studies
l	Informed consent with discussion of the risk of  
 disease and risks and benefits of therapy
Risks of exposure to plasma include infection; 
volume overload and febrile, allergic, anaphylactic 
transfusion reactions, and transfusion-related acute 
lung injury (TRALI).
Patient Eligibility: The use of COVID-19 
convalescent plasma to treat patients includes the 
following criteria:
l Laboratory confirmed COVID-19
l Severe or immediately life-threatening COVID-19
	 m Severe disease is defined as one or more of 
  the following:
	 	 	 n shortness of breath (dyspnea),
	 	 	 n respiratory frequency ≥ 30/min,
	 	 	 n blood oxygen saturation ≤ 93percent,
	 	 	 n lung infiltrates > 50 percent within 24 
    to 48 hours
 m Life-threatening disease is defined as one or 
  more of the following:
	 	 	 n respiratory failure,
	 	 	 n septic shock,
	 	 	 n multiple organ dysfunction or failure
COVID-Donor Eligibility
COVID-19 convalescent plasma must only be 
collected from individuals who meet all routine donor 
eligibility requirements. Donation testing for relevant 
transfusion-transmitted infections must be performed 
and the donation must be found suitable. COVID-19 
convalescent plasma is collected from individuals 
who meet the following qualifications:
l Evidence of COVID-19 documented by a   
 laboratory test either by:
 1. A diagnostic test (e.g., nasopharyngeal swab) 
  at the time of illness OR
 2. A positive serological test for SARS-CoV-2 
  antibodies after recovery, if prior diagnostic 
  testing was not performed at the time 
  COVID-19 was suspected.
l Either one of the following
      1.  Complete resolution of symptoms at least 28 
  days prior to donation
      2.  Complete resolution of symptoms at least 
  14 days prior to donation, AND Negative 
  results for COVID-19 either from one or more 
  nasopharyngeal swab specimens or by a 
  molecular diagnostic test from blood.
l SARS-CoV-2 neutralizing antibody titers, if 
 available
 1. Neutralizing antibody titers of at least 1:160.  
  A titer of 1:80 may be considered acceptable  
  if an alternative matched unit is not available.
 2. When measurement of neutralizing antibody 
  titers is not available, consider storing a 
  retention sample from the convalescent 
  plasma donation for determining antibody 
  titers at a later date.      
                                                                               
Source: UpToDate April 11, 2020, https://www.fda.gov/vaccines-blood-
biologics/investigational-new-drug-ind-or-device-exemption-ide-process-
cber/recommendations-investigational-covid-19-convalescent-plasma.
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Frontline health care workers involved in the 
screening process and providing care for COVID-19 
patients are playing a pivotal role in mitigating the 
effects of the disease in the community. Hence, 
prioritizing the protection of health care workers 
is of utmost importance by prompt provision of all 
essential PPEs. Currently overwhelming demand and 
scarce supply of PPEs has created a serious threat to 
frontline workers across the globe. It has now become 
an essential responsibility of any institute to lay down 
strategies that ensure prompt and regular availability 
of PPEs as well their rational use. For the effective 
utilization required Risk assessment. Following are 
the generic recommendations for the usage of PPE 
during COVID pandemic among health care workers:
1) The type of PPE used will vary according to the 
 setting, type of personnel, and activity (require 
 risk assessment).
2) Those involved in direct care of COVID-19 
 patients should use PPE according to indications. 
3) For aerosol-generating procedures and support 
 treatments (tracheal intubation, noninvasive 
 ventilation, tracheotomy, cardiopulmonary 
 resuscitation, manual ventilation before 
 intubation, and bronchoscopy) use respirators, eye 
 protection, gloves and gowns; aprons should also 
 be used if gowns are not fluid-resistant.
Recommended PPE during the outbreak of COVID-19 
outbreak, according to the setting, personnel, and type 
of activity:
Optimizing the Availability and Rational Use 
of Personal Protective Equipments (PPES) 
Among Health Care Workers
Dr Moiz Ahmed Khan
Clinical Microbiology
Setting Target personnel or patients Activity Type of PPE or procedure
Screening
Clinical triage 
for prioritization 
of care according 
to severity (e.g. 
Manchester 
classification) 
should be performed 
in separate area for 
individuals with 
symptoms and signs
Health care workers Preliminary 
screening not 
involving direct 
contact.
•	 Maintain physical distance of at least 1 meter.
•	 Ideally, build glass/plastic screens to create a barrier 
between health care workers and patients
•	 No PPE required.
•	 When physical distance is not feasible and yet no patient 
contact, use mask and eye protection.
Patients with 
symptoms suggestive 
of COVID-19
Any •	 Maintain physical distance of at least 1 meter.
•	 Provide medical mask if tolerated by patient.
•	 Immediately move the patient to an 
isolation room or separate area away from 
others; if this is not feasible, ensure spatial distance of   
at least 1 meter from other patients.
•	 Perform hand hygiene and have the patient 
perform hand hygiene
Patients without
symptoms suggestive 
of COVID-19
Any •	 No PPE required
•	 Perform hand hygiene and have the patient 
perform hand hygiene
Patient room/ward Health care workers Providing 
direct care to 
COVID-19 
patients, in 
the absence 
of aerosol- 
generating 
procedures
•	 Medical mask
•	 Gown
•	 Gloves
•	 Eye protection (goggles or face shield)
•	 Perform hand hygiene
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Setting Target personnel or patients Activity Type of PPE or procedure
Health care workers Providing direct care 
to COVID-19 patients 
in settings where 
aerosol- generating 
procedures are 
frequently in placeii
•	 Respirator N95 or FFP2 or FFP3 standard, or equivalent.
•	 Gown
•	 Gloves
•	 Eye protection
•	 Apron
•	 Perform hand hygiene
Cleaners Entering 
the room of 
COVID-19 
patients
•	 Medical mask
•	 Gown
•	 Heavy-duty gloves
•	 Eye protection (if risk of splash from organic 
material or chemicals is anticipated)
•	 Closed work shoes
•	 Perform hand hygiene
Visitors Entering the 
room of a 
COVID-19 
patient
•	 Maintain physical distance of at least  1 meter
•	 Medical mask
•	 Gown
•	 Gloves
•	 Perform hand hygiene
Laboratory Lab technician Manipulation of 
respiratory samples 
Specimen handling 
for molecular testing 
would require BSL-
2 or equivalent 
facilities.
Handling and 
processing of 
specimens from 
cases with suspected 
or confirmed 
COVID-19 infection 
that are intended 
for additional 
laboratory tests, 
such as hematology   
or blood gas 
analysis,
should apply standard 
precautions
•	 Maintain physical distance of at least 1 metre
•	 Medical mask
•	 Eye protection
•	 Gown
•	 Gloves
•	 Perform hand hygiene
Administrative areas All staff, including 
health care workers.
Administrative 
tasks that do not 
involve contact with 
COVID-19 patients.
•	 Maintain physical distance of at least 1 metre
•	 No PPE required
•	 Perform hand hygiene
In the scenario of severe shortage of PPE despite 
application of the above-mentioned strategies, it 
is crucial to ensure to protect frontline health care 
workers. This includes urgent increased production 
of PPE, including, if needed, through advance market 
commitments, public-sector mandated scale up of 
production by the private sector, pursuing donation 
options, international solidarity through financial 
support of PPE purchase and distribution for the needs 
of the most vulnerable countries, and engaging with 
the general public to prevent irrational use of PPE at 
community level, among other strategies.
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Setting Target personnel or patients Activity Type of PPE or procedure
Screening/triage Health care workers Preliminary 
screening not 
involving direct 
contact
•	 Maintain physical distance of at least 1 metre.
•	 Ideally, build a glass/plastic screen to create a 
barrier between health care workers and patients
•	 No PPE required
•	 When physical distance is not feasible and yet no 
patient contact, use mask and eye protection.
•	 Perform hand hygiene
Patients with 
symptoms suggestive 
of COVID-19
Any •	 Maintain spatial distance of at least 1 metre.
•	 Provide medical mask if tolerated.
•	 Perform hand hygiene
Patients without 
symptoms suggestive
of COVID-19
Any •	 No PPE required
•	 Perform hand hygiene
With the human race constantly evolving and 
improvising through the ages, the microorganisms 
did not seem to have been left behind at all. Infact, 
every few decades they make sure to make their 
presence felt (not that they need to) globally by 
making a magnanimous entry and a grand exit. 
Pandemics have been mankind’s oldest enemy, the 
earliest reported pandemic dates back to 165 AD and 
was known as Antonine Plague. At a glance, all of 
these pandemics have maintained their individuality 
in terms of causative organisms, their vector, mode of 
transmission, signs and symptoms etc. But that one 
thing that has been unanimously followed by them 
is the mass death they caused before finally saying 
Ciao! Here are few of the famous pandemics and their 
unforgettable exits:
1. Plague Of Justinian- No one left to die:
With its arrival in Constantinople in 541 CE after the 
plague-ridden fleas hitched a ride on the black rats 
that snacked on the grain, this pandemic which got 
its name from a land conquered by Emperor Justinian 
over the Mediterranean Sea spreaded over Europe, 
Asia, North Africa and Arabia killing an estimated 
30 to 50 million people, perhaps half of the world’s 
population.
Causative organism: Yersinia pestis.
Estimated death: 30-50 million.
2. Black Death- The invention of Quarantine:
800 years later Yersinia pestis made an impactful 
comeback and this time with quite a grim name The 
black death, it hit Europe in 1347 and finally bid 
adieu in 1351 with a death of 200 million people on 
its name.  Though it is said to have killed more people 
than WWII, it did brought the idea of Quarantine as 
a saviour. Imposed by Venetian laws as “terentino”, 
it was first implemented on the arriving sailors for 
30 days and was later extended to 40 days forced 
isolation.
Causative organism: Yersinia pestis.
Estimated death: 200 million.
3. The great Plague of London- Sealing up the 
sick:
The plague didn’t seem to leave the British capital 
the easy way and it experienced around 40 outbreaks 
in 300 years (1348-1665) killing 20 percent of its 
population. As the saying goes desperate times call 
for desperate measures, the Englishmen started 
separating and isolating the sick, homes stricken by 
plague were marked with a bale of hay strung to a 
pole outside. The family members of the infected 
person had to carry a white pole when out in public, 
cats and dogs were massacred since they were 
believed to carry the disease and the dead were buried 
in mass graves. Red crosses were painted on their 
Grand Exit of The World’s Famous Pandemics
Dr Tamana Asghari and Dr Khurram Minhas 
Histopathology
JUNE 2020 VOL 46, ISSUE 2
20
doors along with a plea for forgiveness: “Lord have 
mercy upon us”.
Causative organism: Yersinia pestis.
Estimated death: 100,000 people in seven months.
4. Smallpox- The first vaccine:
Smallpox was endemic to Europe, Asia and Arabia 
for centuries but its arrival in 15th century with 
the European exploreres bought devastation to the 
indigenous population of US and Mexcio. 90 to 95 
percent of the indigenous population of Americas 
were wiped out over a century and the population of 
Mexico went down from 11 million to one million. 
18th century saw the coming of smallpox vaccine 
in quite a dramatic way, a British doctor Edward 
Jenner, after learning that the milkmaids who were 
infected with cowpox virus were immuned to 
smallpox, inoculated his gardener’s nine year old son 
with a milder cowpox virus before exposing him to 
smallpox and voila!! In 1980 WHO finally declared 
the complete eradication.
Estimated death: 56 million.
5. Cholera- A new way into public health research:
Tens of thousands became prey to Cholera in early 
to mid19th century in England. The then theory of it 
being spread by foul air prompted Dr John Snow that 
there was more to this rapidly fatal disease than what 
meets the eye. And with his integrated investigations 
of hospital records, morgues and precise location of 
outbreak, the Broad Street pump for drinking water 
was found to be the culprit behind the outbreak that 
claimed 500 lives in just over 10 days. Though cholera 
is still prevalent in some parts of third world countries 
lacking proper sanitization but the overall education 
of urban sanitization has been widely accepted by 
many.
Causative organism: Vibrio cholera.
Estimated death: Approximately one million.
Risk assessment is a systematic process of 
collecting data and evaluating the likelihood and 
outcomes of exposure to workplace hazard(s) and 
so that appropriate risk control measures can be 
implemented to reduce the risk to an acceptable 
level. It is recommended to start with performing 
a local risk assessment for each process step, that 
is, from sample collection to testing and reporting. 
Certain hazards will then be considered for each 
process step, such as aerosol exposure or eye splash 
during sample processing; infectious biological 
specimen spill or leakage that can elevate the 
level of risk. For each identified risk, appropriate 
risk control measures should be selected and 
implemented, to mitigate the residual risks to an 
acceptable level.
In the context of SARS-CoV-2 pandemic, a risk 
assessment exercise was done for processes 
and procedures that are performed in Section of 
Chemical Pathology. The exercise was led by 
the Sectional safety officer, faculty and manager. 
The team reviewed the laboratory processes and 
procedures to identify the potential hazards, 
followed by evaluation of the risk associated 
with all procedures and control measures which 
can be implemented to avoid risk to our staff. 
A risk control strategy was developed based on 
international guideline and strategies on biosafety 
and biosecurity. Once these control measures 
were implemented another review was carried 
out by the team to again assess the risk.Different 
types of specimen received at the Section of 
Chemical Pathology are shown in table 1. It is 
recommended that all laboratories should perform 
risk assessment activities to assess and mitigate the 
risks associated. 
COVID-19 & Risk assessment for Clinical 
Chemistry Procedures
Ms. Iffat Arman and Dr Hafsa Majid 
Clinical Chemistry
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Emergence of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) causing 
coronavirus disease 2019 (COVID-19), the World 
Health Organization and the Centers for Disease 
Control and Prevention (CDC) has released 
documents to provide interim biosafety guidelines 
for the collection, handling, and testing of clinical 
specimens that might contain SARS-CoV-2.
WHO guidelines suggests all specimens (swabs, 
body fluids, blood, feces) must be considered as 
potentially infectious, and appropriate PPE must be 
donned. However Prior studies on the coronaviruses 
showed that a much lower concentration of the virus 
was noted in stool, urine, and blood so the risk to the 
laboratorian can be mitigate while using standard 
blood borne pathogen biosafety level (BSL)–2 
precautions. Aerial transmission is considered the 
major exposure risk to the coronaviruses such as 
SARS-CoV-2 however currently information is still 
not available to define specifically the infectious 
dose for SARS-CoV-2. As a standard for any 
laboratory biosafety program, it is also important 
to realize that the first step to consider is to identify 
hazards by performing a biological risk assessment 
as described below: 
Safety Considerations in the Laboratory 
Testing of Specimens Suspected or Known 
to Contain the Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2)
Sony Siddiqui
Molecular pathology
Table 1: Types of Specimen, High Risk Activities and Risk Mitigation Strategies (Taken from WHO-Laboratory testing for 
coronavirus disease (COVID-19) in suspected human cases. Interim guidance, 19 March 2020)
Specimen Type
Serum/Plasma/
Whole blood 
Specimen
CSF Specimen
Urine Specimen
Fecal Specimen
Breath Specimen
Sweat specimen
High Risk Activities and 
Concentration of virus
Low viral concentration.
Centrifugation is a risk 
for aerosol generation.
highly infectious1
Not established yet2
highly infectious2
highly infectious
highly infectious
Risk Mitigation strategies adopted
n Within-lab movement and non-essential handling/processing minimized
n All samples treated as potentially infectious, wear surgical mask, gloves and  
 full sleeves gowns at all times
n After centrifugation, wait for 10 minutes before opening the centrifuge. 
 In case of Breakage follow the defined protocol
n While handling breath and fecal specimen, Perform sample processing/analysis  
 in Biosafety cabinets. 
n While collecting/processing/analyzing fecal/breath/sweat specimen: treat all  
 samples as infectious, wear N-95 mask, goggles, double gloves and full sleeves  
 gowns.
n Liquid waste disposal process: use 5% Hypochlorite, to prevent splash exposure  
 wear face shields, surgical mask, full sleeves gowns and handle carefully. 
1. Earlier studies on COVID-19 from Wuhan China have reported cases where specific SARS-CoV-2  
 RNA was not detected in the nasopharyngeal swab but was detected in a CSF 
 (https://doi.org/10.1016/.ijid.2020.03.062)
2. Duration and frequency of shedding of COVID-19 virus in stool and potentially in urine is unknown.   
 However warlier reports of COVID-19 have reported that shedding and thereby transmittance of virus is 
 through oral–fecal route (https://www.tandfonline.com/doi/full/10.1080/222 21751.2020.1729071)  
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Table 1: Simplified Biological Risk Assessment
Focus  Processes
Risk characterization Identify hazards: Classify the potential for exposure (mode of transmission, organism concentration,  
 virulence, potential for spill or inhalation) ,determine likelihood and consequence of a specific risk)
Risk mitigation strategies Identify required safety practices to address the risks (PPE, engineering controls, training, operating  
 procedures) 
Workforce Assess competency and experience of laboratory personnel Identify an appropriate training program  
 Enroll staff in an occupational health program
Topic Processes to Consider
Training Donning and doffing of PPE, specimens collection, Packaging and shipping , waste management
Equipment Certified BSC, Centrifuge with sealed rotor or safety cups 
Inventory control Adequate supply of specimen collection devices ,disinfection material, transport materials 
Communication Open lines with the medical care team Collaborations in place with the state/local public health 
 laboratory
The CDC suggests standard practices used in the 
laboratory during the manipulation of potentially 
infected specimens performed in a certified class 
II BSC within the BSL-2 laboratory, appropriate 
physical containment devices should be used such 
as centrifuge with safety buckets or sealed rotors, 
eye and face protection, double gloves, and fit-tested 
N95 respirator or surgical mask if N95 respirator 
is not available. These Standard precautions should 
be applied for aliquoting or diluting specimens, 
inoculating bacterial or mycological culture media, 
performing diagnostic tests that do not involve 
propagation of viral agents in vitro or in vivo, nucleic 
acid extraction procedures involving potentially 
infected specimens, and preparation of chemical or 
heat fixing of smears for microscopic analysis. 
For virus isolation in cell culture and initial 
characterization of viral agents recovered in cultures 
of SAR2-CoV specimens, the CDC suggests that 
work should be performed in a BSL-III laboratory 
while using BSL-III practices (to include fit-tested 
N95 respirators or powered air-purifying respirators). 
In general, while working within the laboratory 
environment, regulatory standards require that all 
health care facilities provide the appropriate personal 
protective equipment (PPE) for the laboratorians, 
that personnel be instructed in the proper use of this 
PPE, the equipment being used in the laboratory 
be maintained and safe, and written procedures for 
the procurement, transportation, and handling of 
patient specimens be available.  Basic Core Processes 
to Support Laboratory Biosafety Practices are 
summarized as follows:  
From the standpoint of the histopathology laboratory, 
the processing of frozen sections from a possible case 
of COVID-19 should be performed only in a cryostat 
where aerosols can be contained while wearing the 
appropriate PPE. Any SARS-CoV-2 specimens that 
have been formalin fixed and paraffin embedded, 
however, should be inactivated based on the previous 
information reported for the inactivation of SARS-
CoV. 
The recommendations are often fluid when 
responding to a new pathogen, strict adherence to 
the suggested safety practices may not be the best 
approach and should be based on the needs of the 
specific facility. As a part of this process, each 
laboratory should conduct a facility-specific risk 
assessment that reviews the procedures performed, 
identifies the hazards involved in the processes and 
procedures, determines the competency level of the 
personnel who perform the procedures, and evaluates 
the equipment and facility design.
Summarized from 
Peter C. Iwen, Karen L. Stiles, SM, Michael A. 
Pentella. Safety Considerations in the Laboratory 
Testing of Specimens Suspected or Known to Contain 
the Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS-CoV-2).Am J Clin Pathol 2020; XX:1–4 DOI: 
10.1093/AJCP/AQAA047
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“The key question: did the patient die from 
COVID-19 or with COVID-19?” pointed out by 
Dr Sanjay Mukhopadhyay (Director, Pulmonary 
Pathology at Cleveland Clinic) in this recent research 
study.  It comprised of complete, comprehensive, 
detailed autopsy reports of two COVID-19 deceased 
patients in Oklahoma, USA, it is first of its kind 
report published in an English-language peer-
reviewed journal. Earlier Chinese literature review 
based on postmortem lung core biopsies, from 
COVID-19 patients have all described similar 
histopathological changes including Diffuse alveolar 
damage (DAD) in most , with superimposed 
bacterial pneumonia in one and several nonspecific 
changes like edema, patchy inflammation, exudates 
(fibrinous/proteinaceous), mononuclear inflammatory 
infiltrates, giant multinucleated cells etc. The 
objective of this study was to offer insight based on 
complete autopsy on underlying pathology. After 
proper biosafety and infection control practice 
Oklahoma forensic pathologists with adequate PPE 
conducted the autopsies. 
The first decedent was a 77-year-old male known 
case hypertension, Deep venous thrombosis 
(DVT), status post total knee replacement (TKR), 
cholecystectomy and splenectomy, with complaints 
of fever and chills for 6 days. There was no travel 
or exposure history. He experienced shortness of 
breath, suffered sudden cardiac arrest during transfer 
to urgent care, and died soon after reaching the 
hospital. Postmortem nasopharyngeal swabs and 
lung parenchymal swabs were positive for SARS-
CoV-2, however basic respiratory pathogen panel 
was negative. Histological findings in the lungs 
revealed patent airways, no mucus plugging, DAD 
with hyaline membrane formation and mild chronic 
interstitial inflammation comprising of mainly 
lymphocytes in airway mucosa. T-lymphocytes 
were positive by immunohistochemistry for CD3, 
CD4 and CD8. Other significant findings were 
coronary artery disease with no myocarditis, 
arterionephrosclerosis, and a right renal mass 
(oncocytoma).
Autopsy Findings in COVID-19 Deceased 
Patients 
Dr Sahar Suleman and Dr Nasir Ud Din
Section of Histopathology
BA
Figure 1A. Diffuse alveolar damage in the acute 
stage. Note hyaline membranes (arrow). B). Patchy 
interstitial chronic inflammation. This image is 
taken from one of the few areas where interstitial 
inflammation was obvious even at low magnification. 
In most areas, the inflammatory infiltrate was very 
sparse or absent.
The second decedent was a 42-year-old male known 
case of myotonic muscular dystrophy, status post 
cholecystectomy.  He had a short history of fever, 
cough and shortness of breath, no travel or exposure 
history. Two days before his demise he started having 
abdominal pain. CT chest preceding death showed 
bilateral ground-glass opacities and consolidations. 
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In the advent of the COVID-19 pandemic, various 
biosafety precautions have been advised for healthcare 
workers. One of these precautions is the use of N95 
respirators while working in a situation where there 
is a possibility of exposure to aerosols, i.e. droplets 
smaller than 1.0 micron in size that do not settle down 
within three feet of the patient. This may occur while 
suctioning airways, intubating patients, being in a 
room with an intubated patient collecting respiratory 
samples, or centrifuging clinical material which may 
contain the virus. The N95 respirators are so named 
because they can the filter or prevent the passage of 
>95 percent particles 0.3 microns or more in size. 
Donning, Doffing and Fit Testing of N95 
Respirators
Dr Joveria Farooqi
Clinical Microbiology
The steps of donning the N95 mask are as given in Table 1
Step 1: Check integrity of the mask.
Step 2: Perform hand hygiene before touching the mask. Hold 
the mask in the palm of your hand with the straps hanging 
below.
Donning N95 Respirators
Mask must not be cracked, wet, folded or soiled. The mask must 
seal well (Step 5)
However, he passed away due to cardiac arrest after 
few hours in hospital. Postmortem nasopharyngeal 
swabs were positive, and lung parenchymal swabs 
were negative for SARS-CoV-2. Basic respiratory 
pathogen panel was negative but bacterial cultures 
were positive for nontoxigenic Escherichia coli, 
Proteus mirabilis, and Candida tropicalis. Histological 
findings in the lungs revealed airspaces filled 
by mixture of neutrophils and histiocytes (acute 
bronchopneumonia) with rare aspirated vegetable 
particles. No DAD or airway mucus plugging. IHC 
results were same as case1 along with CD68 positive 
macrophages. Other findings were liver cirrhosis, 
gynecomastia, testicular atrophy, nephrosclerosis, 
mild coronary atherosclerosis no myocarditis.
The authors concluded that patients may occasionally 
die of other disease processes although being positive 
for COVID-19 as illustrated in case two; who “died 
of acute bacterial bronchopneumonia likely caused 
by aspiration, therefore, this patient likely died with 
COVID-19, not from COVID19”. The reports also 
denied presence of viral myocarditis which is being 
currently speculated by community of physicians.  
They believe these autopsies has allowed adequate 
collection of involved tissue hence increasing 
accuracy of reporting, also multiple organs can be 
assessed simultaneously.
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Step 3: Position the mask in front of your face, covering nose 
and mouth, with straps hanging over your hand
Step 4: Move the top strap over your head and above your ear, 
move the lower strap below your ear around the neck.
Step 5: Using index and middle fingers of both hands press 
down on the metal bit on the bridge and mold it according to the 
shape of your nose and facial structure. Do not pinch the bridge 
as it can tent the mask and result in leaking.
Step 6: Test the mask for leakage or seal by placing your hands 
around the edge and exhaling. If you feel air leak from the 
bridge, press down on the metal bit and retest for leakage. If 
air leaks from the sides, adjust the straps till a proper seal is 
achieved. The mask edges should be sealed to your face and no 
air should leak from them if the efficiency of the mask is to be 
ensured.
Seal test must be performed every single time the mask is 
worn.
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Fit-testing
To confirm if the make of N95 is actually appropriate 
for you and it really is sealing well to your face, fit 
test may be performed. If fit-test is passed, it remains 
valid as long as the make of the mask does not 
change, and the individual does not have any great 
change in facial structure due to accident, surgery 
or significant change in weight. A fit-testing kit is 
required to perform a fit test.
The steps of fit-testing are given in Table 2
Step 1: The person being tested should not have ingested 
anything in the last 30 minutes. Sensitivity of the taste 
receptors of the person being tested is checked by administering 
a puff of the diluted reagent through a hand-held nebulizer (both 
provided in the kit) while wearing a hood over their head. This 
reagent may be sweet (saccharin) or bitter (Bittrex) in taste. The 
individual is asked if they can taste the reagent; if not, another 
puff is administered every 20 seconds till the person can taste 
it or 20 puffs are complete. The person is asked to remember 
the taste, then asked to gargle and rinse out the taste completely 
from their mouth.
If the reagent cannot be tasted after 20 puffs, the fit test cannot 
be performed for this person using this reagent, it may be 
attempted with another reagent eliciting an alternate taste. Courtesy: 3M™ FT-10 (sweet) and 3M™ FT-30 (bitter) Qualitative Fit 
Testing Kits. https://youtu.be/PthSES4O9d8 
Step 2: Ask the person being fit-tested to don the N95 and 
seal test it. Now place the hood over the person’s head and 
administer five puffs of the undiluted fit-testing reagent and ask 
them to breathe normally for 30 seconds. Ask them to indicate 
if they can sense the taste they were sensitized with. If yes, the 
fit test has failed, ask them to remove mask rinse mouth repeat 
donning and seal test and restart from step 2. If they cannot 
taste it, proceed to next step.9
Step 3: Administer another five puffs of reagent and ask the 
person being tested to take deep breaths for 30 seconds. If they 
can still not taste the reagent, then proceed to step 3. If they 
can, then doff mask, rinse out taste, and repeat from step 2.
Step 4: Administer another five puffs of reagent and ask the 
person being tested to move their head side to side and up and 
down, bend at the waist, reach up and to the side in measured 
movements. Continue these movements for 30 seconds. If they 
can still not taste the reagent, then proceed to step 5. If they 
can, then doff mask, rinse out taste, and repeat from step 2.
Step 5: Administer another five puffs of reagent and ask the 
person being tested to talk continuously for 30 seconds. You 
may keep a written passage for them to read out. If they can still 
not taste the reagent, then fit test is passed. If they can, then doff 
mask, rinse out taste, and repeat from step 2.
Fit testing being performed in Aga Khan University Hospital, Karachi. 
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The steps of doffing the N95 mask are as given in Table 3
Step 1: Perform hand hygiene and hold the lower strap from the 
back and pull it off
Step 2: Pull the upper strap from the back and pull it over the 
head
Step 3: Hold the mask from the straps and store in a paper bag 
labeled with your name or discard if soiled, cracked or wet. 
Perform hand hygiene.
Doffing N95 respirators
In this era of COVID-19 pandemic, it has been a 
challenge to fight this novel virus efficaciously without 
compromising well-being of health professionals. The 
frontline healthcare providers and staff, who are in direct 
contact with the patient or deal with Aerosol Generating 
Procedures (AGP) have high risk of transmission of this 
infection and therefore need effective protection.  Below 
is the summary of the rational use of personal protective 
equipment (PPE) for coronavirus disease (COVID-19) 
as proposed by WHO on 19th, March 2020 for health 
care and community setting. Though these are interim 
guidance but have been well formulated to achieve 
maximum protection. PPE includes gloves, medical 
masks, goggles or a face shield, and gowns. For specific 
procedures, respirators (i.e. N95 or FFP2 standard or 
equivalent) and aprons. (Figure 1)
Personal Protective Equipment (PPE) 
for Coronavirus Disease (Covid-19)-As 
Recommended by World Health Organization 
Dr Shayan Sirat
Radiology 
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Preventive Measures for COVID-19 Disease
Based on the available evidence, the COVID-19 virus 
is transmitted between humans through droplets and 
close contact. There is no airborne transmission. 
Personnel in close contact or caring for COVID-19 
patient are at most risk of contracting infection.
Preventive and attenuating measures are key. 
The most effective preventive measures in the 
community include:
 • Performing hand hygiene frequently with an 
  alcohol-based hand rub if your hands are not 
  visibly dirty or with soap and water if hands 
  are dirty;
 • Avoiding touching your eyes, nose, and 
  mouth;
 • Practicing respiratory hygiene by coughing 
  or sneezing into a bent elbow or tissue and 
  then immediately disposing of the tissue;
 • Wearing a medical mask if you have 
  respiratory symptoms and performing hand 
  hygiene after disposing of the mask;
 • Maintaining social distance (a minimum 
  of 1 meter = 3 feet) from persons with 
  respiratory symptoms.
Additional precautions to be taken by frontline health 
care workers includes using PPE appropriately; this 
involves selecting proper PPE and being trained in 
how to put on, remove, and dispose of it. Besides PPE, 
administrative and environmental and engineering 
controls, has also been described in WHO’s Infection 
prevention and control of epidemic- and pandemic-
prone acute respiratory infections in health care.  
These controls are summarized here. 
Administrative controls include safeguarding 
resources for infection prevention and control 
(IPC) measures, such as appropriate infrastructure, 
development of clear IPC policies, facilitated access to 
laboratory testing, appropriate triage and placement of 
patients, adequate staff-to-patient ratios, and training 
of staff.
Environmental and engineering controls aim at 
minimizing the spread of infection and pollution 
of surfaces and inanimate objects. They include 
providing adequate space to allow physical distance of 
at least one meter (three ft) to be maintained between 
patients and between patients and health care workers 
and assuring availability of well-ventilated isolation 
rooms for patients with suspected or confirmed 
COVID-19.
Recommendations for optimizing the availability 
of PPE. In view of the global PPE shortage, the 
following strategies can facilitate optimal PPE 
availability (Figure 2).Figure 1: Personal protective equipment, https://www.usatoday.com/
in-depth/news/2020/03/31/coronavirus-protection-what-health-care-
workers-need-stay-safe/2917179001/
Figure 2: Strategies to optimize the availability of PPE
Minimize PPE
need
Optimize PPE
availability
Coordinate
PPE supply
chain
Use PPE
appropriately
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1. Minimize the need for PPE:
The following interventions can minimize the need 
for PPE while protecting health care workers and 
others from exposure to the COVID-19 virus in health 
care settings.
 • Prefer using telemedicine to evaluate 
  suspected cases of COVID-19.
 • Use physical barriers such as glass or plastic 
  windows, in areas such as triage, the 
  registration desk and pharmacy window to 
  reduce exposure.
 • Health care workers not involved in direct 
  care of COVID-19 patients should be 
  restricted from entering the isolation rooms.
 • To minimize the number of times a room 
  is entered, consider bundling activities e.g. 
  check vital signs during medication 
  administration or have food delivered by 
  health care workers while they are performing 
  other care.
 • Ideally, visitors shall not be allowed, but 
  if unavoidable, restrict the number of visitors 
  to isolation areas; reduce the amount of time 
  visitors are allowed to spend in the area; and 
  provide clear instructions about how to put on 
  and remove PPE and perform hand hygiene to 
  ensure that visitors avoid self-contamination.
2. Ensure PPE use is rational and appropriate: 
PPE should be used based on the risk of exposure 
(e.g. type of activity) and the transmission dynamics 
of the pathogen (e.g. contact, droplet or aerosol). The 
overuse of PPE will have a further impact on supply 
shortages. Following recommendations, if observed, 
will ensure rational use of PPE.
 • The type of PPE used when caring for 
  COVID-19 patients will vary according to the 
  setting and type of personnel and activity 
  (Table 1).
 • Health care workers involved in the direct 
  care of patients should use the following PPE: 
  gowns, gloves, medical mask, and eye 
  protection (goggles or face shield).
 • Specifically, for aerosol-generating 
procedures (e.g. tracheal intubation, 
non-invasive ventilation, tracheostomy, 
cardiopulmonary resuscitation, manual 
ventilation before intubation, bronchoscopy) 
health care workers should use respirators, 
eye protection, gloves and gowns; aprons 
Table 1 Recommended PPE during COVID-19 outbreak
Health care workers 
-providing direct care to 
COVID-19 patients- medical 
mask, gown, gloves, eye 
protection (goggles or face 
shield)
Health care workers 
- aerosol-generating 
procedures performed on 
COVID-19 patients- respirator 
N95 or FFP2 standard, or 
equivalent, gown, gloves, eye 
protection, apron.
Cleaners- entering the 
room of COVID-19 patients-
medical mask, gown, heavy 
duty gloves, eye protection 
(if risk of splash from organic 
material or chemicals) boots 
or closed work shoes.
Visitors- entering the room 
of a COVID- 19 patient- 
medical mask, gown, gloves.)
should also be used if gowns are not fluid 
resistant.
In addition to using the appropriate PPE, frequent 
hand hygiene and respiratory hygiene should 
always be performed. PPE should be discarded in 
an appropriate waste container after use, and hand 
hygiene should be performed before putting on and 
after taking off PPE. 
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Radiology Department Preparedness for 
COVID-19
Dr Ismail Alvi and Prof Tanveer ul Haq
Radiology Department.
The Coronavirus Disease 2019 (COVID-19) pandemic 
began in December 2019 in Wuhan, China. The 
outbreak is due to severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection. In March 
2020, the World Heath Organization declared 
COVID-19 as a pandemic, due to the rapid increase in 
the number of cases outside China. 
Due to the nature of the outburst in China, Chest 
CT findings (e.g., peripheral ground-glass infiltrates 
and/or organizing pneumonia) temporarily became 
part of official diagnostic criteria of COVID-19 as a 
substitute for viral nucleic acid testing. In addition 
to COVID-19, Radiology departments have to cater 
a large number of other patients and make sure that 
there is no infection spread from the confines of 
the department, while maintaining high quality of 
diagnostic and interventional services. 
AIMS
Radiology department, according to the Hospital 
infectious disease department prepared a set of 
policies and procedures tailored to department’s 
needs. 
The aims were  
 a) to reduce patient morbidity and mortality 
  related to infection through early diagnosis  
  and appropriate treatment
 b) to prevent disease dissemination to our   
  employees, patients and the general 
  community. 
 c) to maintain radiology diagnostic and 
  interventional services for the entirety of the 
  hospital and health system.
Outpatient Services
With the guidelines of the infectious disease 
department, radiology department setup patient 
screening desk (Figure 1) at the entrance of 
department, where screening of all patients and 
visitors in carried out. A second layer of screening for 
symptoms is carried out at the radiology front desk.
Patient screening is also undertaken at the time of 
radiology exam scheduling on phone. For elective 
radiology exams, suspected patients are referred to 
the designated hospital screening area (initially CHC) 
for further workup. In addition to patient screening 
this desk helps in enforcing the ‘one patient one 
attendant’ policy.
Furthermore, radiology department has limited 
the number 
of elective 
appointments 
to ensure 
that social 
distance can 
be maintained 
during 
department 
stay. This 
is being 
accomplished 
via automated 
patient texting 
services, direct 
calls to patients 
from radiology 
Figure 1 - Screening desk at Radiology Entrance.
Figure 2 - Safe Distance Floor markers at Radiology Reception
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appointment desk and through Radiology coordinator 
assistance. The seating arrangement (Figure 2) in the 
waiting areas have also been transformed to ensure 
social distancing. 
Inpatient and ER Services
After coordination with inpatient areas, all radiology 
requests should mention COVID status of the patient 
in one of the following categories.
 a) Negative for COVID-19.
 b) Suspected for COVID-19.
 c) Positive for COVID-19.
Separate procedure rooms in all modalities (x-rays, 
CT-scan, MRI) are allocated for negative and 
suspected/positive patients for COVID-19. Similarly, 
separate portable X-Ray and Ultrasound machines are 
designated for COVID areas and general inpatients. 
Imaging of COVID-19 Positive or Suspected 
Patients
The decision to image patients who are COVID-19 
positive or suspected is based on how the imaging 
will impact patient care. Currently we do not routinely 
use imaging for COVID-19 screening, but imaging 
is performed in COVID-19 positive or suspected 
patients, to rule out other diagnoses that can be 
treated, including pulmonary embolism. In addition, 
emergent imaging may be necessary for evaluation 
of other urgent conditions, including stroke, trauma, 
infection and other disease conditions.
Clinics and inpatient units are directed to call ahead 
regarding COVID-19 positive or suspected cases so 
that precautionary preparations to receive the patient 
can be made moreover we have assigned the pathway 
through which we transport the patient to radiology 
so our elective patients are not exposed with these 
population and GR,US, CT and MRI system to 
provide services for these patients. 
Implementation of “social distancing” strategies 
for Staff, Trainees, and Faculty
The radiology reading room has been restructured 
to promote social distancing (Figure 5). A number 
of diagnostic workstations have been shifted to other 
locations (like radiology library, teaching room, 
etc.) so that social distancing can be practiced easily. 
The reading room is equipped with hand sanitizers 
and alcohol wipes (Figure 6) for disinfection of the 
computer peripherals (microphone, keyboard, mouse).
Figure 3 - Waiting area with distant seating
Figure 4 - Housekeeping staff cleaning with hypochlorite solution.
Figure 5 - Social distancing in Radiology Reading Room.
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With the aim to decrease foot traffic in radiology 
reading rooms’ remote consultations by telephone 
rather than in-person is encouraged. 
Recurring departmental meetings and multiple 
clinical conferences have been moved to video 
conferencing. We are exploring strategies to allow 
diagnostic radiologists to work from home and 
developing guidance for when this is appropriate. 
In addition to these measures, and taking in 
consideration of the workload, the staff roster has 
been changed to allow only the essential workforce 
presence in the department.
In conclusion, the department’s response, policies and 
protocols to this pandemic have been adapted up to 
the maximum standards achievable.
COVID-19: An Alarm Bell for Healthcare 
System in Pakistan!
Dr Mohammad Zeeshan 
Microbiology 
Heraclitus, a Greek philosopher once said, ‘the 
only constant in life is change’. And how so true 
this statement is! We constantly discover, invent, 
and improve to survive and grow in this world. 
Interestingly, for those of us who don’t improve, life 
creates situations and circumstances that force us to 
bring in the much needed change. 
The COVID-19 Pandemic is one such situation for 
healthcare system in Pakistan. Today, the entire 
healthcare industry from basic healthcare units 
to multidisciplinary hospitals, has been given a 
wake-up call. Medical personnel are grappling to 
provide services and care to their communities, and 
desperately putting their lives at stake to save patients. 
The gaps and holes, inefficiencies and discriminations 
in our system have been laid bare for all. Fixing this 
falling system is a tall ask, and would require purity 
of intent and persistence; however, few aspects need 
to be address urgently.  
Personnel and Institutional Safety 
The concept of safety within our healthcare system 
is almost non-existent and barring few exceptions, a 
functional Hospital Safety Committee is an abstract 
notion in most health facilities. Similarly, the 
wellbeing of healthcare providers is a long neglected 
case. The attitude of both the government and hospital 
managements towards medical staff’s safety is 
appallingly indifferent. 
In recent COVID-19 scenario, the unprecedented 
demand but interrupted, inadequate supplies of PPEs 
(personnel protective equipment) has hit the panic 
button for health care systems across the entire globe. 
And in Pakistan, we are struggling even more. We 
claim our healthcare staff to be frontline troopers, and 
yet we fail to provide appropriate, ample safety gears 
for them. The staff is exposed to health threatening 
environment, putting their lives at jeopardy. This also 
Figure 6 - Hand sanitizers and Alcohol wipes for Disinfection of 
Workstation peripherals.
Lessons to learn from COVID Pandemic to effectively cope with new, more severe 
contagious diseases in future. 
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has a ripple effect; these staff become source of spread 
to other patients, attendants, colleagues, and even 
their families.  
Therefore, now is the right time for all small scale 
healthcare centers and multidisciplinary institutes 
to enforce a Hospital Safety Committee. For smaller 
outfits, any senior doctor or head nurse with training 
in infectious disease and an understanding of 
safety regulations can be given the responsibility to 
oversee affairs. For hospitals, a multi-disciplinary 
committees should be formed that reports to the 
facility CEO or Administrator. This committee must 
preempt situations and liaise with health ministry 
and provincial governments to ensure availability of 
protective gears, testing and lifesaving equipment 
and medicines through local and international 
manufacturers. The committee should also ensure 
safety regulations are being fully followed vis-à-
vis usage and disposal of gears and equipment, and 
handling and disposal of corpses in case of infectious 
epidemic.   
Training of Healthcare Workforce 
The entire healthcare workforce requires regular 
upgrading of skills and rigorous training in new 
approaches. This sadly is another neglected aspect 
of our system. Despite being frontline defense, our 
nurses and paramedics are not trained at grass root 
level to handle expected panic situations such as 
infectious disease outbreaks. Large medical facilities 
are better off in coping with these situations through 
mobilizing local resources and international health 
agencies. However, BHUs and smaller medical 
centers, which cater to the masses, struggle to serve. 
The government should engage large hospitals to 
assist in training these healthcare providers with 
regular training (at cost) and secondments to keep 
abreast. There can also be cascade training programs 
where senior professional from each facility can be 
trained as Master Trainers to disseminate learning to 
others.
 
Data Sharing
  
During any ongoing outbreak, epidemic or large-
scale calamity, it is imperative to share reliable, real 
time data with national and international public 
health agencies. This helps in devising strategies to 
combat the situation, formulate or modify policies 
and guideline, and avoid duplication of efforts 
across. Therefore, our healthcare system must 
have a uniform, structured, user friendly database, 
compatible and integrated with other national and 
global databases. There should also be clear SOPs for 
sharing such data of reportable diseases with national 
health agencies on regular basis.
Diagnostic Facilities
A rare, inspiring medical moment during this 
COVID-19 Pandemic was Germany’s exemplary 
effort of investing preemptively in laboratory 
diagnosis, massive testing-kit production and 
performing screening at mass level against 
modern-day Frankenstein which lead to effectively 
and proactively implemented policies for early 
controls. The survival ratio of Germans is far more 
encouraging contrary to the rest of Europe. For 
Pakistan, it is a pressing need to develop capacity for 
rapid procurement of reliable, authentic diagnostic 
kits to perform testing with recommended validation. 
Facilities with better infrastructure and workforce 
situation must facilitate resource limited setting in 
their capacity building. 
Infection Prevention and Control Department  
An active, efficient Infection Prevention and Control 
Department is considered a linchpin in any healthcare 
facility. The core responsibility of this team is to 
ensure spread control of infections between patients, 
healthcare personnel and visitors by breaking the 
chain of transmission through introducing and 
implementing stringent protocols and SOPs. 
In our hospitals and clinics, the position of Infection 
Preventionists is regrettably understated. This 
professional has never been prioritized to be in the 
list of essentials by healthcare managers. Therefore, 
while reflecting on COVID-19 and conceiving 
post pandemic strategies, the roles of Infection 
Preventionists must considered critical and an 
empowered infection prevention team must be put in 
place. 
n Objectives and Responsibilities
 The objectives and responsibilities of this 
 department must be clearly specified with a 
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 strong underlying principle of well-being and 
 safety of workers, patients and visitors, and 
 ensuring a safe premises. 
n Standard Operation Procedures 
 The department must establish clear SOPs for the 
 Healthcare facility and workforce with additional 
 rules and regulations for any functional teams and 
 sub-committees.  
n Administrative Strategies
 Implementation of SOPs has to be ensured  
 through a dedicated and professional ‘Safety 
 Officer’ and ‘Infection Control Practitioner’. In 
 case of resource limitation, a single Healthcare 
 professional be designated instead of a team. This 
 individual can work in close contact and under the 
 supervision of a senior doctor.   
n Risk Assessment 
 The infection prevention and control department 
 or individual is responsible for developing 
 a ‘risk assessment and mitigation framework’ 
 for the Healthcare facility and staff. Based on a 
 multidisciplinary approach, the framework should 
 define leveled scenarios from low risk to high and 
 state procedures for key aspects such as 
 modification in engineering systems, change 
 in hospital traffic flow, use of PPEs, proper waste 
 disposal, etc.
The COVID-19 Pandemic is a testing time for all. 
There is sickness and death; and the visible future 
is uncertain. The only hope in this maddening fear 
is having a better Healthcare system that can fight 
the pandemic and sustain till help arrives in from of 
vaccine or other treatment. Therefore, we must latch 
on the one opportunity this adversity offers – steer our 
Healthcare system in the right direction. The gaps in 
this system are most visible today. Let’s work together 
– government, large hospitals and medical fraternity – 
to bridge the gaps and build on!
The Covid 19 pandemic has adversely affected our 
lives and the scales of its impact are unprecedented in 
our life time. The deteriorating economic conditions 
lock down, and safety issues of us and the family, 
makes the situation quite stressful and uncertain. In 
view of all this we faced a challenge of continuation 
of educational activities for undergraduate medial 
students so that they continue the learning activities 
without risk of losing an academic year.  We were 
well aware of certain limitations specific for our 
country such as lack of internet access in remote 
areas of the country, laptops accessibility, and trained 
technology savvy man power.  
Detailed plans were devised for delivering content, 
attendance record, assessments, number of sessions 
per day and faculty student adaptability for the online 
platform. As most of the faculty was comfortable with 
delivering face to face sessions and had never used 
an online platform for teaching learning purpose, this 
was and added challenge. Beside this students were 
also thinking it as boring and far-fetched. 
After exploration and thorough discussion with the 
IT team, we decided to use Microsoft teams as an 
online portal that best fit for conducting our classes. 
Following this, we planned a series of scheduled 
training sessions for faculty and administrative staff 
where they received orientation on how to operate 
MS team. Finally we conducted an orientation session 
with the students to inform them regarding the newly 
established online system for learning. Students 
were guided on how to use MS team. In addition, 
we developed video tutorials and easy to follow flow 
charts to be shared with all faculty members, detailing 
the basics of platform and delivering online sessions. 
To address any issues, separate admin support 
Emergency Online Undergraduate Medial 
Education During COVID 19 
Dr Romana Idrees 
Histopathology 
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Online teaching takes a lot of preparation! Once 
COVID 19 hit Pakistan, as Chair of Endocrine 
and Reproduction Module in Undergraduate 
Medical Education (UGME) at Aga Khan 
University, I was informed to shift the module 
to an online format just few weeks away from 
commencement of the module.  Like everyone 
else we were also not prepared for COVID 19, 
however in order to continuity in teaching-
learning a plan was devised. We knew we will be 
facing hiccups as we had to work with tools we 
were not familiar with. 
Challenges Faced
l Rush to get teaching moved to an online format.
l Poor connectivity was faced by few students and 
 faculty at times during online sessions.
l The myriad complexities involved in moving a 
 face-to-face course into the online format.
l Training of faculty to teach online.
l Students Assessments. 
l Conducting ‘Flipped Class Room’ in an online 
 format. With students feedback we tried to make 
 it case based or with quiz and guided faculty to 
 refrain from didactic online lectures.
l How to teach clinical and communication skills?
Challenges and Success Factors of Going 
Online with the Endocrine and Reproduction 
Module in Undergraduate Medical Education 
at Aga Khan University
Dr Lena Jafri 
Clinical Chemistry
WhatsApp groups were developed for faculty and 
students. These served as command and response 
centers during the online sessions.  Minor hiccups 
like disruptions of internet connection or login issues 
for the students were faced in the first orientation 
session. However, these issues were resolved in real 
time. With the commencement of online teaching we 
were able to complete all the essential component of 
the module in the form of LCF,PBL and tutorials. Few 
Labs were also converted into LCF.The clinical skill 
sessions, sign off labs and few embryology lectures 
will be done one students join back the campus.  
Despite some challenges, we noted few advantages 
of this emergency shift. Faculty members who were 
earlier reluctant to deliver content online or to pre-
record their lectures; were happily recording the 
lecture sessions and/ or converting them as Flipped 
classes. This resulted in providing students an 
opportunity to learn as per their convenience as they 
can review the lecture anytime. We have received 
encouraging and positive students’ feedback as their 
classes schedule is almost the same keeping them 
busy. We conducted online mid module and end of the 
module formative exams comprising of 20-30 MCQs 
and two SAQs.The passing percentage was 70 percent. 
All students took the exam and found it useful in 
enhancing learning.
In addition there was an increase in student 
attendance and engagement. During the online 
lectures, students put forth numerous logical 
questions on the session chat which were addressed 
by the teachers. Therefore, the fear of lack of connects 
or student interaction was rebutted.  
During this whole exercise we acknowledged the core 
values of teamwork, support from the leadership, 
and consistent effort by the faculty along with the 
eagerness to learn displayed by our very academically 
gifted students. These were the major driving forces 
which made this learning experience a great success. 
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Success Factors
l Planning in no time! Find time to plan.
l Creating a Game plan with clear final outcomes.
l Creating a project timeline.
l Clarify for your team the specific set of   
 expectations and responsibilities associated with 
 their roles.
l Recognize and encourage positive energizers in 
 your organization who have interest in your 
 module/ teaching and involve them.
l Experience of Year 2 UGME team. Gave the 
 provision of online training to faculty on how to 
 conduct online lectures and PBLs.
l Available assistance from Office of UGME, Aga 
 Khan University
l Available assistance and experience of institute’s 
 IT and Academics and Blended and Digital 
 Learning Network.
l Tech savvy students. 
l Energized faculty ready to adapt to change.
l Faculty and staff adapted to cope with the 
 situation. 
l Focus on the positive and reframe obstacles into 
 positive challenges.
l Identify strengths of your team members, and use 
 to the benefit of the team. 
l Two years’ experience of running our module 
 in blended format with handful of faculty and 
 staff trained on virtual learning environment.
l We had Moodle Champs within our Department 
 that we had trained in the past and were engaged.
l Express appreciation to students, faculty and 
 staff (e.g., making appreciative comments, emails 
 and notes a daily practice).
l Staying connected with your module team 
 members, with students, with faculty and staff.
l Due to COVID 19 Pandemic, change was easy!
Recommendations
All involved in teaching should be prepared to teach 
online once in a while because after this pandemic 
is over who knows when a similar situation like this 
may arise again. Sometimes even in harsh weather 
issues like heavy rainfall in Karachi it might be wise 
and more desirable for students and faculty to stay 
home and teach from a distance. It may be wise for 
educational institutes to encourage faculty to spend 
some of their time teaching online to gain experience 
and prepare themselves. As online teaching and 
learning continues to grow, a growing number of 
faculty will be requested or even required to develop 
curricula and teaching in this environment. Beyond 
the pandemic can online teaching learning ever be 
as effective as the face to face traditional teaching 
methodology and is teaching-learning online here to 
stay?
Owing to the leading health crisis of the COVID-19 
pandemic, most educational institutes including 
medical universities worldwide have shut their 
campuses to mitigate the spread. In response, 
teaching is being transformed from physical 
class rooms to online, on an unprecedented 
scale; certainly, with a hand full of trial and 
error and experience building for the educators, 
students, curriculum developers and institutional 
administration. 
Why ‘Microsoft Teams’, for Online Teaching? 
Though there are numerous online platforms 
available for virtual learning, Microsoft Teams 
offers a suite of communication tools that are user 
friendly and more importantly easily accessible 
alongside the company’s Office 365 subscription for 
Adopting Virtual Teaching During the Pandemic-
An Overview of the Utility of ‘Microsoft Teams’ 
from an Educator’s Perspective
Dr Sibtain Ahmed
Clinical Chemistry
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windows at no additional charges. The application 
(app) can be accessed from windows, iOS and 
Android based platforms ranging from PCs to 
handheld devices with internet connectivity on the 
go.
How to Learn, to Use ‘Microsoft Teams’?
To begin with, it is advisable to skim through the 
variety of tutorials, freely available on YouTube 
and Microsoft 365 online help, although mastering 
the utility of the app comes with hands-on real-time 
practice, preferably with a small group initially.  
What are the Features of the App in a Nutshell?
Class rooms which the app defines as ‘TEAMS’ 
can be constructed based on specific criteria. The 
occupancy of the team can range from the entire 
batch for instance for a lecture or a small group of 
students for problem-based learning with facilitator. 
A video chat with up to 250 people at once or a 
live presentation with up to 10,000 people can be 
held via the app. A specific URL or invitation is 
sent by a team owner, allowing the participants to 
connect. Certain topics for discussion can be set 
up within the teams by the teacher which the app 
terms as ‘Channels’. Pupil can reply via text as 
well as images, GIFs. Educators can also use direct 
messages to pursue individual feedbacks. 
Real time online classroom can be scheduled or 
created ad-hoc which the app terms as ‘Meetings’. 
The participants are able to see that a meeting is 
currently in progress and the facilitators have the 
option of sharing their screens. Additionally, the 
app also offers a plugin for Microsoft Outlook to 
invite others into a Teams meeting. This feature 
proves to be handy in cases you want a guest 
lecturer or invited facilitators to join. 
How to Plan a Flipped Classroom with the App?
For the Flip classrooms, the pre reading material, 
videos, animations etc. can be circulated within 
the team using the app. This option is especially 
helpful for those institutes which do not have 
prior virtual learning environment in place like 
MOODLE. 
Is there any option for Assessment?
As far as assessment is concerned, the app has 
a ‘Assignments tab’ which allows teachers to 
distribute, provide feedback, and grade student 
assignments. Pre and Post Test activities for e.g. a 
quiz can also be assigned to students through an 
integration with Office Forms. 
Is there option for Recording and online Cloud-
based Storage?
Another substantial benefit is ease of recording 
lectures and presentations and sharing with the 
team. Also comes built in is shared storage in 
SharePoint Online and participants get personal 
storage in OneDrive, consisting of 2GB for a free 
account and 1TB for a fully licensed Office 365 
account. This resource pack can be utilized by the 
students as well as the teachers from anywhere, 
with merely a phone and internet connectivity for 
future reference and learning without carrying 
heaps of books and notes. 
Does it offer Connectivity with other Apps used 
by the Institution?
Moreover, if there are other tools that your 
institutions have already standardized on like 
ZOOM; Microsoft Teams has an option via “Apps’ 
to connect those apps directly and then switch to 
that platform as per the requirement.
What are the noteworthy advantages of this 
virtual teaching platform?
Furthermore, other numerous advantages include 
cost saving in terms of overhead cost for setting 
up and attending physical classrooms both for the 
institution as well as the students. Space constraints 
specially pre-booking of rooms for classes has been 
overcome by the virtual podium. Disruption of 
educational activities owing to various unfavorable 
circumstances like natural calamities and low and 
order situations in certain locations can no-longer 
become a hindrance for teaching and learning 
activities. With this user-friendly app even for the 
novice users, no hardcore and time-consuming 
trainings are required.
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Any distinct advantage for Postgraduates?
From a medical educator’s standpoint, the 
undergrad medical students have dedicated and 
scheduled learning activities, on the contrary 
postgraduate trainees owing to their workplace 
duties suffer from time constraints and are often 
unable to attend physical class rooms. This is 
where, this app can do wonders, allowing ease of 
learning, live as well as remotely for the trainees as 
well as the ‘busy clinical faculty’.
Are there any Limitations?
On the other side of the picture, there are certain 
limitations associated with this mode of learning. 
The lead is lack of adaptivity, fluctuating comfort 
levels and engagement of students with their online 
instructors or their virtual classmates. Disruption 
in internet services is also a issue in certain 
areas often restricting the use of technology for 
certain users. 
Way Forward 
From a broader perception, changing the mode 
of delivery of education, is not just a switch from 
one app to another, rather it’s about changing 
behavior and habits of the learners and the 
facilitators, that have been ingrained over 
decades. Building effective online classrooms, 
will require self-discipline on both ends, time, 
experience and commitment. However, the present 
world situation has given us all the reasons to move 
online and reform our educational system for better 
productivity.
A Multidisciplinary Conference on ‘Newborn 
Screening for Rare Disorders in Pakistan’ was 
held from March 4th to 7th 2020 at the Aga Khan 
University (AKU), Karachi, Pakistan. Conference 
was arranged by Department of Pathology and 
Laboratory Medicine and the Division of Women 
and Child Health, AKU in collaboration with 
Departments of Biological & biomedical Sciences 
and Obstetrics and Gynecology, AKU and national 
societies including Pakistan Society of Chemical 
Pathologists, Pakistan Medical Association, 
Pakistan Pediatric Association, Pakistan Society 
of Hematology and Pak IMD-Net.  Rare diseases 
affects many aspects of an individual’s life 
including their social, educational and employment 
opportunities and is an emerging global public 
health priority. When consider together, “rare” 
diseases are not so rare after all. According to 
an estimate around 300 million people, i.e. four 
percent of the world’s population suffers from 
these conditions. Therefore public health policies 
at global and national level are needed to address 
this issue. Such a policy is becoming reality 
in many countries around the globe. However, 
non-availability of diagnostic facilities, delayed 
diagnosis, misdiagnosis, difficulty accessing 
appropriate information, difficulty accessing care, 
availability of experts help and poorly coordinated 
care are still the norm for rare disease patients and 
their families in Pakistan. 
In this scenario, it is important for us as a nation 
to think that how can we form collaborations 
to facilitate resource development. Health care 
providers, and experts from the different institutes 
of the country participated in it. The primary 
Reframing rare in Pakistan: An Experience 
of Conducting a Successful Multidisciplinary 
Conference in the face of COVID-19 Uncertainty
Dr Hafsa Majid
Clinical Chemistry.
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aim was to break the silos and bringing synergies 
between healthcare personnel’s working in the 
field of rare diseases in Pakistan, building bridges 
between then, bringing them on one platform 
where they can come together, understand the 
issues of rare diseases and come up with concrete 
steps that can be implemented within tight 
timeframes after the conference.  On February 
1st, the programme looked fine with some 21 oral 
presentations, 70 posters, four pre-conference 
workshops, four international guests and nearly 
15 national experts coming from different cities 
of Pakistan. We also planned four pre-conference 
workshops including ‘Establishing Registries for 
Tracking Patient Outcomes’, ‘Genetic Counseling: 
How to do it right?’, ‘Bioinformatics hands-on on 
IMD genomics’ and ‘Essentials of establishing a 
newborn screening program’. Things were looking 
good. Then Corona hit furiously. In Pakistan the 
first corona patients were reported on February 
26th, 2020, before the meeting even began. We 
were all on tenterhooks, whether our participants 
and speakers, especially international speakers 
will be able to come because of travel restrictions. 
We kept in close contact with them, made back-
up plans in case they were not able to come. Our 
administrative team played an important role in it 
they made sure that all the participants/speakers 
face no hiccups in registrations. Fortunately, 
the most if not all of all of the International 
and National speakers were able to attend the 
conference. And very good discussions were 
generated in all the workshops and conference 
talks, participants were enthusiastic. The workshop 
participants were from all over Pakistan, and 
overwhelmingly engaged into talks, and interactive 
hands-on learning activities. The participants gave 
a good evaluation for each workshop both formally 
and informally indicating that these activities 
helped them brainstorm ideas of common interest. 
It was a huge learning experience for us in terms 
of conducting a conference in these times of 
uncertainty and many of the lessons we learned can 
be applied to future conferences.
Picture 1: Picture of Conference Organizers and Speakers.
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1. As we navigate through the uncertain times of 
‘COVID19’ do you feel the same level of motivation 
every morning while coming to AKU?
Professor Afia: Since the beginning of the lockdown 
in Karachi in March I have been coming to AKU 
everyday with the same zeal and commitment. I feel 
responsible and I am happy to serve my department, 
my institute and my community. As an infection 
control expert, I have also been occupied and engaged 
in various activities related to Covid-19 within the 
institute.
2. What challenges are you facing in a time like 
this and what were the success factors that helped 
you respond to these challenges? 
Professor Afia: These are challenging times 
and we expect our staff to work in such difficult 
circumstances. For me trying to provide safe 
environment for all was one of the major concerns.  
The leadership my peers and colleagues have 
remained connected, supportive and helped me find 
solutions to any kind of problem during these times. 
Despite, the financial constraints, and uncertain 
future both in terms of the disease and their own 
future everyone in my department is still contributing 
for the love of humanity. Everyone at every level has 
been supportive and has been working for humanity 
and I really appreciate it.
3. Was there any 
‘AHA moment’ at 
workplace during 
these difficult COVID 
times?
Professor Afia: The 
AHA moment for 
me was when we 
started the diagnostic 
testing for COVID-19 
patients. With this 
service we were the first ones to serve the community. 
Another big moment was the ‘Fit Test Service’ by 
my department through which till to date more than 
thousand personnel have been trained which was all 
possible with mutual teamwork.
4. Any advice to prestige readers on how to stay 
positive in this dire time?
Professor Afia: Stay connected with junior staff and 
keep supporting each other. Do not limit your efforts 
to your section, department or hospital in short have 
a holistic approach. We as medical practitioners are 
trained to cope with challenges and to serve mankind 
in any circumstances. Our seniors in this profession 
have set the bar high for us to follow and we will 
continue to endeavor. 
The Best of the Recent Past
#COVID19 # #Pathologists #Followtheirlead #changeagents 
Interview of the Chair of Pathology and Laboratory Medicine, Professor Afia Zafar 
Recorded by Dr Lena Jafri 
JUNE 2020 VOL 46, ISSUE 2
41
1. How is the typical day at work now different 
from the one before the COVID-19 outbreak?
Professor Zahra: For the past two months the work 
days have been long and engaging – it’s a marathon 
rather than a sprint.  There is an urgency in the 
laboratory to work through the COVID-19 testing 
at different levels. It took us some time to set up 
workflows that could be easily followed as the teams 
have grown. The operations of testing are running 
smoothly with the cooperation of all sectional faculty 
and technical staff who have been fantastic. Further, 
we are constantly trying to bring in new innovations 
into the testing, pooling of PCR samples in batches, 
validating new kits, trying out alternate specimens, 
each day brings new queries and due to the nature of 
the disease there is an urgency to deal with things as 
rapidly as possible.
2. What challenges did you face in establishing 
and leading COVID-19 testing at AKUH clinical 
lab and what were the success factors that helped 
you respond to these challenges?
Professor Zahra: The first challenge was 
procurement of necessary reagents when we decided 
to go ahead and establish a laboratory developed 
test (LDT) when we saw the virus spreading in 
and outside of Wuhan, China in January 2020.  
Waiting three weeks for reagents seemed like 
eternity. However, the reagents did come in and 
with the help our fantastic faculty and staff team 
at Molecular Pathology we were able to set up the 
assay. Dr. Kiran Iqbal and Dr. Najia Ghanchi have 
been relentlessly working on improving the testing 
methods and have done validations and verifications 
of many commercial assays for SARS-CoV-2 as 
we now run CE-IVD marked assays.  The whole 
team is involved in this effort. Dr. Zeeshan, Section 
Head has facilitated all 
the necessary ordering, 
all of us have a rapid 
reporting rota. Nazneen 
Islam, the lab manager 
has done a fantastic job of 
coordinating staff rotas, 
training, coordination 
with purchase. A special 
thanks to Sohail Baloch 
for keeping up with all of 
our demands.  Due to the 
biosafety requirements of working with SARS-Cov-2 
testing collaboration with Section of Microbiology, 
Dr Rumina and Dr. Erum who have helped use the 
Biosafety Level 3 laboratory as effectively as possible. 
The lab management has been very supportive and 
it has been a multi-dimensional and multi-sectional 
effort to keep up the requirements for COVID 19 
testing.
3. How do you feel when you see your laboratory 
team work tirelessly day and night responding to 
patients need in this time of crisis?
Professor Zahra: I feel very proud that we have been 
able to sustain the workflow, work ethics and do our 
best each day in this demanding time.  I do worry 
about keeping them safe and feel that the PPE needs 
to be taken care of at all time.
4. How rewarding it is to be working behind 
the scenes and to tackle this pandemic head-
on supporting patient who are battling with 
COVID-19?
Professor Zahra: I believe we are already seeing the 
impact that we at AKUH have had on diagnostics of 
COVID-19 testing at the institutional, provincial and 
The Best of the Recent Past
#COVID19 # #Pathologists #Followtheirlead #changeagents 
 
Interview of the Professor of Pathology and Laboratory Medicine, 
Professor Zahra Hasan
Recorded by Dr Najia Ghanchi 
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national levels.  We are involved in guidance to other 
institutions for SARS-CoV-2 testing. Initially for RT-
PCR and now regarding the serology based assays as 
well. The innovations and improvements we bring in 
can benefit a maximum number of people when we 
work cooperatively. 
5. Times of crisis have historically also been 
opportunities for change. Are you optimistic that 
as we emerge from this, it could be a chance to be a 
health care facility a lot more equipped to face the 
challenges like this better than before?
Professor Zahra: Yes, indeed. The Clinical 
Laboratory management, Hospital management and 
the Dean have all been involved in making this a 
concerted and rapid effort.  We have learned a lot 
the past two months and hope that it will leave us 
in a better place to work quickly if faced with other 
challenges. 
6. As per daily updates, the incidence of 
COVID-19 is on rise. How is your team responding 
to meet the needs of huge number of patients 
coming in requiring rapid testing?
Professor Zahra: We are staying on track with our 
plans for testing through the day with regular cut-
offs.  We have involved additional staff from other 
sections to organize the set-up of testing. It has helped 
to streamline the organization of samples, preparation 
of batches and set up of large batches for the high-
throughput testing by sending people to BSL3 in 
pairs.  We have learned that as long as every step of 
the process is organized properly it is possible to scale 
up effectively.
7. Do you see a process map in near future 
that will support the extensive patient testing 
throughout the country?
Professor Zahra: I believe we have the organization 
capacity to support expanded testing throughout 
the country provided that bottlenecks such as space 
for sample organization, storage and additional 
equipment can be provided. We have an opportunity 
to impact COVID-19 diagnostics throughout Pakistan
The Best of the Recent Past
#COVID19 # #Pathologists #Followtheirlead #changeagents 
 
Interview of the Chief Resident of Pathology and Laboratory Medicine, 
Dr Ruhul Quddus
Recorded by Dr Anila Rashid
1. As we navigate through the uncertain times of 
‘COVID19’ do you feel the same level of motivation 
every morning while coming to AKU?
Dr. Ruhul Quddus: Yes, I do feel the same level 
of motivation each day. Although in the start there 
were uncertainties but just like any other medical 
professional I relied on my clinical instincts regarding 
the situation and continued to practice the preventive 
and precautionary standard practices accordingly
2. What challenges are you facing in a time like
this and what were the success factors that helped
you respond to these 
challenges? 
Dr. Ruhul Quddus: 
The challenges that I 
personally and in general 
most of us faced in the 
start were: the risk of 
exposure to or contracting 
the COVID. Also, I had 
to come up with a plan 
in order to manage the 
situation, according to the hospital guidelines, i.e. 
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The Best of the Recent Past
#COVID19 # #Pathologists #Followtheirlead #changeagents 
 
Interview of the Medical Officer of Pathology and Laboratory Medicine, 
Dr Aniqa Arshad Raza
Recorded by Dr Siraj Muneer
1.	 As we navigate through the uncertain times
of ‘COVID19’ do you feel the same level of motivation 
every morning while coming to AKU?
Dr Aniqa: Yes, it’s true that the prevailing situation
due to spread of COVID-19 is unprecedented yet
realizing the hopefulness and trust of the patients on 
us to keep our doors open even during times of 
pandemic, makes me feel motivated. I believe the 
AKU plays an important role in keeping us motivated
as well, everyone here follows the safe practice 
recommendations, we are 
provided with appropriate PPEs 
and the trust that here at AKU 
staff safety comes first and 
foremost. I feel blessed to be 
working at AKU and be able to 
serve the humanity through this 
noble profession. 
2. What challenges are you facing in a time like
this and what were the success factors that helped
reducing the exposure without compromising the 
work and patient care. Additionally, to look after, 
to morally support and to counsel my colleagues/
residents/medical officers that were on frontline or 
those who went to isolation or quarantine were at 
times overwhelming.
As in every case, it wasn’t a one-man effort at all. 
We achieved success through coordinated teamwork 
which in part was also contributed by the ability of 
everyone to listen to us and to understand us. The 
other half of success, obviously, is everyone staying 
positive dissociating all negative news/information, 
and sticking to the standard precautions and 
preventive measures.
3. Was there any ‘AHA moment’ at workplace
during these difficult COVID times?
Dr. Ruhul Quddus: One of the big moment for me, 
despite all the negativity, was seeing the commitment 
of faculty, residents, medical officers who continued 
their duties and the facilitation by others staff. Some of 
our colleagues actually going on the frontline was a real 
inspiration. While others volunteered for and conducted 
awareness sessions and facilitated training sessions.
4. Any advice to prestige readers on how to stay
positive in this dire time?
Dr. Ruhul Quddus: Always stay positive and be 
hopeful. Avoid anxiety-provoking news and articles 
on social media. Do something that brings you joy and 
which keeps your time and mind occupied. You can 
utilize your time to study, read or complete your other 
unfinished work and researches. Share your anxiety 
and fears with those colleagues who can give you 
positive and optimal response.
5. As an expert what changes do you propose
to the institute to gear up for another such
eventuality in the future?
Dr. Ruhul Quddus: In any emergent or disastrous 
situation, time is of the critical essence. There should 
be contingency plan in place all the times which can 
be used should the situation or need arise. It will help 
us saving the time and utilizing this time directly on the 
implementation of the plan. We should also have backup 
plans in case if we cannot cope with the situation or if the 
primary contingency plan fails. In order to contribute to 
general public, we should also have good social media 
coverage in order to reach to them. It will also help us to 
conduct public awareness sessions.
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you respond to these challenges? 
Dr Aniqa Raza: Direct interaction with the patients 
who are suffering from this lethal virus can expose 
even the doctors to critical hazards, especially 
patients who are asymptomatic. However our 
repeated trainings have ingrained in us to follow 
the safe practice guidelines and use appropriate 
PPEs. With the support of our head, chief resident 
and cooperation of my colleagues we were able to 
respond to all challenges with the determination to be 
successful in this turbulent time. 
3. Was there any ‘AHA moment’ at workplace 
during these difficult COVID times? 
 
Dr Aniqa: Yes, I’m amazed at the team spirit with 
which we are all enthusiastically working together to 
achieve a common goal of countering COVID-19 and 
I’m proud of being an active member. It was also an 
‘AHA moment’ for me to be chosen to provide training 
of propharangeal swabs and nasopharangaeal swabs 
techniques to fellow doctors and technical staff to 
defeat this pandemic. Also safe COVID-19 testing zone 
for sampling of patients for screening Corona was an 
experience that amplified my own expertise and further 
enhanced my understanding about the pandemic.
4. Any advice to our prestigious readers on how 
to stay positive in this dire time?
Dr Aniqa: I would like to encourage my counterparts 
to keep serving the humanity indefatigably for the 
triumph of health over disease. To all those heroes I 
dedicate this quote, “Not all angels have wings some 
have stethoscopes”. They are truly angels. For the 
public I would advise to STAY HOME STAY SAFE 
unless it’s extremely important to go out. In that case 
don’t forget to adopt all the precautionary measures.
5. As an expert what changes do you propose to 
the institute to gear up for another such eventuality 
in the future?
Dr Aniqa: A pandemic situation demands a rapid 
response and huge capacity building. To treat and 
accommodate maximum number of patients while all 
departments of the hospital should remain operational 
too is a mammoth task. Training of the paramedics 
should be multiplied further to respond to any 
emergency situation in a better way. The proper gear 
and equipment should be in functional position and in 
sufficient quantity to deal unforeseen circumstances 
of high magnitude.
Picture 1: Some of the Histopathologists reporting during COVID 19 pandemic days
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Picture 2: CME Webinar “Covid-19 Imaging, An Essential Tool to Diagnose & Treat” held on 19th April, 2020
Presentations, Course design and Moderation by AKU Radiology faculty (Dr Nadeem Ahmad, Dr. Kiran Hilal and
Dr Muhammad Azeemuddin
Picture 3: Staff at the Section of Chemical Pathology has been working day and night to deliver accurate and timely 
reports. Picture shown is of COVID-19 warriors from the Section of Chemical Pathology taken in April 2020.
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Picture 4: Multiple COVID-19 Awareness and training sessions were conducted for the staff at the Section of Chemical 
Pathology. Picture shown is of one such awareness session conducted on 27th February 2020 at the Section of Chemical 
Pathology.
Picture 5: Health care team, Ultrasound Suite-Department of Radiology during COVID times.
Polaroid
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Picture 6, 7 & 8: N95 Fit testing performed by microbiology faculty and residents for health care workers of Aga Khan Hospital 
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Picture 9: Meet the Molecular Pathology Faculty who developed the COVID-19 test at Aga Khan University. Reporting 
first case of SARS-CoV2 from Pakistan.
Picture 10: COVID 19 warriors at section of molecular pathology, AKUH clinical laboratories working day and night 
performing complex critical testing and delivering quality results on time
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Picture 11: COVID warriors working in Biosaftey level 3 (BSL-3) laboratory taking appropriate precautionary measures 
performing SARS CoV 2 testing according to international standards.
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Picture 12 & 13: In service teaching and training session for health care workers regarding Infection prevention in health care 
setting during COVID 19 pandemic at Abbasi Shaheed hospital by Microbiology faculty and resident
Picture 14: COVID-19 Sample Collection Booth at Aga Khan University Karachi. These single modular booths provide a 
physical barrier separating patients and the healthcare staff. 
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Picture 15: Dr Bushra Moiz delivered talk on Inherited thrombophilia testing in a CME “Reframe Rare in Pakistan”, 
held at AKU in March 2020
Picture 16: COVINAR, special course series with over 3500 registrations, organized jointly by DCPE and DED.
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THE AGA KHAN UNIVERSITY HOSPITAL 
 
CLINICAL LABORATORIES 
 
UPDATE 
 
Detection of Novel Coronavirus-2019 (COVID-19) 
 
by Real Time PCR 
 
VOL. XXVI No. 3, 2020 
 
Introduction 
 
Coronaviruses, named for the crown-like spikes on their surface. Around the world, most common 
mild to moderate respiratory coronavirus infections in humans are by 229E, NL63, OC43, and 
HKU1. Sometimes coronaviruses that infect animals (zoonotic viruses) can evolve and transmit to 
humans and become a new human strain. Two zoonotic coronaviruses, SARS-CoV (2002-2003) 
and MERS-CoV (since 2015), are known to cause severe illness in humans. A recent example of 
such emergence from Wuhan, China is the novel coronavirus, COVID-19. 
 
Person-to-person spread of COVID-19 is via respiratory droplets produced when an infected 
person coughs or sneezes. The incubation period is 2-14 days. Symptoms include fever, cough 
and shortness of breath; suspicion increases when patient has history of travel to affected areas 
(especially China and other Far Eastern countries) in the last 2 weeks. Suspected cases with 
respiratory infection and recent travel to affected countries should be tested for COVID-19. All 
such patients who need hospitalization for management, should be tested at the earliest and 
contact isolation precautions instituted till COVID-19 infection has been ruled out. 
 
Principle of the Assay: 
 
Real-time (RT- PCR) assays for the in vitro qualitative detection of Novel Coronavirus-2019 
(COVID-19) is used. Results interpretation is based on detection of fluorescent signals. 
 
Specimen Collection: 
 
Note: For initial diagnostics testing of COVID 19, Centers for Disease control and 
Prevention(CDC) and World Health Organization(WHO) recommend to collect nasopharynx and 
oropharynx swab in a same tube to increase the viral load. 
Use only synthetic fiber swabs with plastic shafts. Do not use calcium alginate swabs or swabs 
with wooden shafts as they may inhibit PCR testing or inactivate some viruses. 
 
Collecting the Oropharynx swab. 
 
Insert swab into the posterior pharynx and tonsillar areas. Rub swab over both tonsillar pillars and 
posterior oropharynx and avoid touching the tongue, teeth, and gums. 
 
Collecting the Nasopharyngeal swab.  
 
Insert swab through the nares parallel to the palate (not upwards) until resistance is encountered 
or the distance is equivalent to that from the ear to the nostril of the patient indicating contact with 
the nasopharynx. Gently, rub and roll the swab. Leave the swab in place for several seconds to 
absorb secretions before removing. 
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Sputum  
 
Educate the patient about the difference between sputum and oral secretions. Have the patient 
rinse the mouth with water and then expectorate deep cough sputum directly into a sterile screw-
cap collection cup or sterile dry container 
  
Upper respiratory specimens including nasopharyngeal or oropharyngeal swabs in a special tube 
containing Universal Transport Medium (available from the clinical laboratory) 
 
Lower respiratory specimens including Broncho-alveolar Lavage (BAL), tracheal aspirates and 
sputum in sterile container. 
 
Reporting Schedule: 
 
COVID-19 virus RT-PCR is performed and reported daily if specimen is received before cut off 
11:00 am (excluding Sunday) 
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